###begin article-title 0
###xml 47 52 <span type="species:ncbi:9606">human</span>
Sonic hedgehog is a potent chemoattractant for human monocytes: diabetes mellitus inhibits Sonic hedgehog-induced monocyte chemotaxis
###end article-title 0
###begin p 1
###xml 462 463 462 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 535 536 535 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 585 586 585 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1002 1003 997 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
###xml 475 483 <span type="species:ncbi:9606">patients</span>
###xml 725 730 <span type="species:ncbi:9606">human</span>
###xml 1240 1245 <span type="species:ncbi:9606">human</span>
The aim of the present study was to evaluate the expression of hedgehog (Hh) signaling molecules and the chemotactic activity of Sonic hedgehog (Shh) in monocytes from control (CTR) and diabetic patients with or without coronary artery disease (CAD). Previously several studies demonstrated that exogenous administration of Shh can induce angiogenesis and accelerate repair of ischemic myocardium and skeletal muscles. Blood samples were collected from (1) CTR (n = 25); (2) patients with stable CAD without diabetes mellitus (CAD-DM, n = 10); and (3) with stable CAD with DM (CAD+DM, n = 15). Monocytes were isolated by Percoll gradient and subjected to PCR and chemotaxis analysis. Hh signaling molecules were expressed in human monocytes, and Shh-induced monocyte chemotaxis. Shh-stimulated migration of monocytes from CTR measured 172.5 +/- 90% and a maximal stimulation was observed at Shh concentration of 1 mug/ml. However, Shh failed to induce migration of monocytes from CAD+DM (94.3 +/- 27%, P < 0.001 vs. CTR). The impaired response to Shh was associated with strong transcriptional upregulation of the receptor Ptc, while expression of downstream molecules was not altered. Moreover, Ptc is strongly expressed in macrophages of human aortic atherosclerotic plaque. Thus, Shh is a potent chemoattractant for monocytes and it activates classical signaling pathways related to migration. The Shh signaling was negatively affected by DM which might be involved in the pathogenesis of DM-related complications.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 660 662 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 804 806 800 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
The Hedgehog (Hh) pathway is highly conserved in evolution and Hh proteins are essential for cell fate decisions during development and homeostasis of adult tissues. Three proteins compose the Hh family: Sonic (Shh), Indian (Ihh) and Desert (Dhh) hedgehogs. All Hh proteins bind to a surface receptor complex comprised of two transmembrane proteins Patched (Ptc), a receptor for Hh proteins and Smoothened (Smo), a signal transducer. It has been demonstrated that all Hh members Shh, Ihh and Dhh proteins bind the receptor Ptc with similar affinity, however, they vary with regard to their potency. The rank order of potency was generally Shh >/= Ihh >/= Dhh [27]. The Hh signal is then mediated by the Gli family transcription factors (Gli 1-3), which regulate the expression of different target genes [10].
###end p 4
###begin p 5
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 646 648 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 1049 1050 1049 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 1156 1166 1156 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 1168 1170 1168 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 1228 1229 1228 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 1273 1275 1273 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 1323 1325 1323 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1378 1380 1378 1380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 1156 1166 <span type="species:ncbi:7227">Drosophila</span>
###xml 1232 1235 <span type="species:ncbi:10116">rat</span>
There is increasing evidence for the role of Hh signaling in vascularization and neovascularization. Recently, it has been shown that activation of Hh signaling is critical for coronary development and sufficient to promote formation of coronary vessels in the embryonic and adult heart [13, 22, 29]. Shh gene therapy could promote both angiogenesis and arteriogenesis and protect from ischemic injury in rodent and large animal models [21]. However, the mechanism how Shh induces neovascularization is still unknown. It has been shown that blood circulating mononuclear cells play an important role in both artheriogenesis and angiogenesis [15, 32]. They adhere to the arterial wall, infiltrate and stimulate vessel growth in the ischemic tissue by the release of cytokines, growth factors and proteases. Several recent studies have suggested a role of Hh signaling in the control of motility and migration of multiple cell types. Hedgehog proteins act as a chemoattractant on isolated axons, guide neuronal migration during embryonic development [6], serves as an attractive cue to guide germ cell migration through the embryo to form primitive gonad in Drosophila [12], promote the migration of endothelial progenitor cells [1], rat activated pancreatic stellate cells [33], embryonic endothelial cells and fibroblasts [18] as well as optic nerve oligodendrocyte precursors [24]. However, nothing is known about migration control of immune cells by Hh proteins. Here, we tested the hypothesis whether Shh stimulates monocyte chemotaxis. Our results demonstrate that Shh is a potent chemoattractant for peripheral monocytes and it activates classical signaling pathways related to cellular migration such as G-proteins or PI3K. Moreover, we provide the first piece of evidence that pathological conditions such as diabetes mellitus (DM) significantly impair Shh-induced chemotaxis, which is accompanied by elevated expression levels of Ptc. Thus, these data indicate that the Hh signaling pathway (1) is involved in monocyte biology and (2) is negatively affected by the cardiovascular risk factor DM.
###end p 5
###begin title 6
Methods
###end title 6
###begin title 7
Study population
###end title 7
###begin p 8
###xml 389 390 389 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 698 699 698 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 840 841 840 841 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c</sub>
###xml 954 955 954 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1048 1049 1048 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1272 1273 1272 1273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1313 1314 1313 1314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1324 1331 1324 1331 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1331 1388 1331 1388 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="9">Clinical characteristics of control subjects and patients</p>
###xml 1331 1388 1331 1388 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="9">Clinical characteristics of control subjects and patients</p></caption>
###xml 1388 1388 1388 1388 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1393 1394 1393 1394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1388 1399 1388 1399 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CTR, <italic>n</italic>&#160;=&#160;25</th>
###xml 1407 1408 1407 1408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1399 1413 1399 1413 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CAD&#8722;DM, <italic>n</italic>&#160;=&#160;10</th>
###xml 1421 1422 1421 1422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1413 1427 1413 1427 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CAD+DM, <italic>n</italic>&#160;=&#160;15</th>
###xml 1427 1428 1427 1428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1427 1434 1427 1434 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic> value</th>
###xml 1388 1434 1388 1434 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"/><th align="left">CTR, <italic>n</italic>&#160;=&#160;25</th><th align="left">CAD&#8722;DM, <italic>n</italic>&#160;=&#160;10</th><th align="left">CAD+DM, <italic>n</italic>&#160;=&#160;15</th><th align="left"><italic>P</italic> value</th></tr>
###xml 1388 1434 1388 1434 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left"/><th align="left">CTR, <italic>n</italic>&#160;=&#160;25</th><th align="left">CAD&#8722;DM, <italic>n</italic>&#160;=&#160;10</th><th align="left">CAD+DM, <italic>n</italic>&#160;=&#160;15</th><th align="left"><italic>P</italic> value</th></tr></thead>
###xml 1434 1445 1434 1445 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Age (years)</td>
###xml 1445 1458 1445 1456 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">59.9&#160;&#177;&#160;12.7</td>
###xml 1458 1470 1456 1466 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">63.7&#160;&#177;&#160;9.9</td>
###xml 1470 1479 1466 1473 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">66&#160;&#177;&#160;11</td>
###xml 1479 1484 1473 1478 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.579</td>
###xml 1434 1484 1434 1478 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Age (years)</td><td align="left">59.9&#160;&#177;&#160;12.7</td><td align="left">63.7&#160;&#177;&#160;9.9</td><td align="left">66&#160;&#177;&#160;11</td><td char="." align="char">0.579</td></tr>
###xml 1484 1487 1478 1481 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BMI</td>
###xml 1487 1489 1481 1483 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ND</td>
###xml 1489 1499 1483 1491 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">26.8&#160;&#177;&#160;2</td>
###xml 1499 1509 1491 1499 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">26.3&#160;&#177;&#160;5</td>
###xml 1509 1509 1499 1499 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1484 1509 1478 1499 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">BMI</td><td align="left">ND</td><td align="left">26.8&#160;&#177;&#160;2</td><td align="left">26.3&#160;&#177;&#160;5</td><td align="left"/></tr>
###xml 1522 1523 1512 1513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1509 1527 1499 1517 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Male gender, <italic>n</italic> (%)</td>
###xml 1527 1534 1517 1524 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">12 (48)</td>
###xml 1534 1540 1524 1530 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7 (70)</td>
###xml 1540 1546 1530 1536 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">9 (60)</td>
###xml 1546 1551 1536 1541 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.470</td>
###xml 1509 1551 1499 1541 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Male gender, <italic>n</italic> (%)</td><td align="left">12 (48)</td><td align="left">7 (70)</td><td align="left">9 (60)</td><td char="." align="char">0.470</td></tr>
###xml 1551 1578 1541 1568 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Cardiovascular risk factors</td>
###xml 1551 1578 1541 1568 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Cardiovascular risk factors</td></tr>
###xml 1578 1598 1568 1588 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;CAD history (years)</td>
###xml 1598 1599 1588 1589 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1599 1607 1589 1595 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">10&#160;&#177;&#160;8</td>
###xml 1607 1614 1595 1600 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">9&#160;&#177;&#160;8</td>
###xml 1614 1619 1600 1605 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.578</td>
###xml 1578 1619 1568 1605 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;CAD history (years)</td><td align="left">0</td><td align="left">10&#160;&#177;&#160;8</td><td align="left">9&#160;&#177;&#160;8</td><td char="." align="char">0.578</td></tr>
###xml 1643 1644 1629 1630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1619 1648 1605 1634 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Family history of CAD, <italic>n</italic> (%)</td>
###xml 1648 1655 1634 1641 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">11 (44)</td>
###xml 1655 1661 1641 1647 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7 (70)</td>
###xml 1661 1667 1647 1653 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7 (47)</td>
###xml 1667 1672 1653 1658 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.231</td>
###xml 1619 1672 1605 1658 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Family history of CAD, <italic>n</italic> (%)</td><td align="left">11 (44)</td><td align="left">7 (70)</td><td align="left">7 (47)</td><td char="." align="char">0.231</td></tr>
###xml 1687 1688 1673 1674 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1672 1692 1658 1678 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Hypertension, <italic>n</italic> (%)</td>
###xml 1692 1699 1678 1685 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">12 (48)</td>
###xml 1699 1705 1685 1691 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4 (40)</td>
###xml 1705 1711 1691 1697 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">9 (60)</td>
###xml 1711 1716 1697 1702 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.284</td>
###xml 1672 1716 1658 1702 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Hypertension, <italic>n</italic> (%)</td><td align="left">12 (48)</td><td align="left">4 (40)</td><td align="left">9 (60)</td><td char="." align="char">0.284</td></tr>
###xml 1726 1727 1712 1713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1716 1731 1702 1717 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Smoking, <italic>n</italic> (%)</td>
###xml 1731 1737 1717 1723 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6 (24)</td>
###xml 1737 1743 1723 1729 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3 (30)</td>
###xml 1743 1749 1729 1735 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6 (40)</td>
###xml 1749 1754 1735 1740 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.607</td>
###xml 1716 1754 1702 1740 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Smoking, <italic>n</italic> (%)</td><td align="left">6 (24)</td><td align="left">3 (30)</td><td align="left">6 (40)</td><td char="." align="char">0.607</td></tr>
###xml 1765 1766 1751 1752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1754 1770 1740 1756 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Diabetes, <italic>n</italic> (%)</td>
###xml 1770 1775 1756 1761 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0 (0)</td>
###xml 1775 1780 1761 1766 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0 (0)</td>
###xml 1780 1788 1766 1774 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">15 (100)</td>
###xml 1788 1788 1774 1774 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1754 1788 1740 1774 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Diabetes, <italic>n</italic> (%)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">15 (100)</td><td align="left"/></tr>
###xml 1788 1811 1774 1797 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Duration of DM (years)</td>
###xml 1811 1812 1797 1798 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1812 1813 1798 1799 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1813 1820 1799 1804 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">8&#160;&#177;&#160;7</td>
###xml 1820 1820 1804 1804 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1788 1820 1774 1804 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Duration of DM (years)</td><td align="left">0</td><td align="left">0</td><td align="left">8&#160;&#177;&#160;7</td><td align="left"/></tr>
###xml 1820 1851 1804 1835 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Patients receiving insulin (%)</td>
###xml 1851 1852 1835 1836 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1852 1853 1836 1837 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1853 1855 1837 1839 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">40</td>
###xml 1855 1855 1839 1839 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1820 1855 1804 1839 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Patients receiving insulin (%)</td><td align="left">0</td><td align="left">0</td><td align="left">40</td><td align="left"/></tr>
###xml 1855 1882 1839 1866 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Patients receiving OHD (%)</td>
###xml 1882 1883 1866 1867 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1883 1884 1867 1868 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1884 1887 1868 1871 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">100</td>
###xml 1887 1887 1871 1871 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1855 1887 1839 1871 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Patients receiving OHD (%)</td><td align="left">0</td><td align="left">0</td><td align="left">100</td><td align="left"/></tr>
###xml 1887 1900 1871 1884 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;FPG (mmol/l)</td>
###xml 1900 1911 1884 1893 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5.5&#160;&#177;&#160;0.7</td>
###xml 1911 1922 1893 1902 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6.3&#160;&#177;&#160;0.7</td>
###xml 1922 1933 1902 1911 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">8.3&#160;&#177;&#160;4.6</td>
###xml 1933 1938 1911 1916 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.048</td>
###xml 1887 1938 1871 1916 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;FPG (mmol/l)</td><td align="left">5.5&#160;&#177;&#160;0.7</td><td align="left">6.3&#160;&#177;&#160;0.7</td><td align="left">8.3&#160;&#177;&#160;4.6</td><td char="." align="char">0.048</td></tr>
###xml 1942 1944 1920 1922 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 1938 1948 1916 1926 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;HbA<sub>1c</sub> (%)</td>
###xml 1948 1950 1926 1928 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ND</td>
###xml 1950 1952 1928 1930 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ND</td>
###xml 1952 1963 1930 1939 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7.3&#160;&#177;&#160;0.6</td>
###xml 1963 1963 1939 1939 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1938 1963 1916 1939 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;HbA<sub>1c</sub> (%)</td><td align="left">ND</td><td align="left">ND</td><td align="left">7.3&#160;&#177;&#160;0.6</td><td align="left"/></tr>
###xml 1963 1984 1939 1960 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Laboratory parameters</td>
###xml 1963 1984 1939 1960 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Laboratory parameters</td></tr>
###xml 1984 2012 1960 1988 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Cholesterol, total (mmol/l)</td>
###xml 2012 2023 1988 1997 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5.9&#160;&#177;&#160;1.3</td>
###xml 2023 2034 1997 2006 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.4&#160;&#177;&#160;0.8</td>
###xml 2034 2045 2006 2015 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.0&#160;&#177;&#160;1.4</td>
###xml 2045 2050 2015 2020 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.283</td>
###xml 1984 2050 1960 2020 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Cholesterol, total (mmol/l)</td><td align="left">5.9&#160;&#177;&#160;1.3</td><td align="left">4.4&#160;&#177;&#160;0.8</td><td align="left">4.0&#160;&#177;&#160;1.4</td><td char="." align="char">0.283</td></tr>
###xml 2050 2075 2020 2045 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;LDL-cholesterol (mmol/l)</td>
###xml 2075 2086 2045 2054 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.0&#160;&#177;&#160;1.2</td>
###xml 2086 2097 2054 2063 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.1&#160;&#177;&#160;0.8</td>
###xml 2097 2108 2063 2072 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.1&#160;&#177;&#160;0.9</td>
###xml 2108 2112 2072 2076 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.16</td>
###xml 2050 2112 2020 2076 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;LDL-cholesterol (mmol/l)</td><td align="left">4.0&#160;&#177;&#160;1.2</td><td align="left">2.1&#160;&#177;&#160;0.8</td><td align="left">2.1&#160;&#177;&#160;0.9</td><td char="." align="char">0.16</td></tr>
###xml 2112 2137 2076 2101 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;HDL-cholesterol (mmol/l)</td>
###xml 2137 2148 2101 2110 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.8&#160;&#177;&#160;1.0</td>
###xml 2148 2159 2110 2119 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.2&#160;&#177;&#160;0.6</td>
###xml 2159 2170 2119 2128 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.0&#160;&#177;&#160;0.3</td>
###xml 2170 2175 2128 2133 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.127</td>
###xml 2112 2175 2076 2133 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;HDL-cholesterol (mmol/l)</td><td align="left">1.8&#160;&#177;&#160;1.0</td><td align="left">1.2&#160;&#177;&#160;0.6</td><td align="left">1.0&#160;&#177;&#160;0.3</td><td char="." align="char">0.127</td></tr>
###xml 2175 2198 2133 2156 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Triglycerides (mmol/l)</td>
###xml 2198 2209 2156 2165 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.8&#160;&#177;&#160;1.2</td>
###xml 2209 2220 2165 2174 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.8&#160;&#177;&#160;0.4</td>
###xml 2220 2231 2174 2183 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.1&#160;&#177;&#160;1.1</td>
###xml 2231 2236 2183 2188 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.638</td>
###xml 2175 2236 2133 2188 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Triglycerides (mmol/l)</td><td align="left">1.8&#160;&#177;&#160;1.2</td><td align="left">1.8&#160;&#177;&#160;0.4</td><td align="left">2.1&#160;&#177;&#160;1.1</td><td char="." align="char">0.638</td></tr>
###xml 2236 2259 2188 2211 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Medication at admission</td>
###xml 2236 2259 2188 2211 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Medication at admission</td></tr>
###xml 2305 2306 2257 2258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2259 2310 2211 2262 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Antiaggregatory therapy (antiplatelet drugs) <italic>n</italic> (%)</td>
###xml 2310 2317 2262 2269 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">11 (44)</td>
###xml 2317 2323 2269 2275 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7 (70)</td>
###xml 2323 2329 2275 2281 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7 (47)</td>
###xml 2329 2334 2281 2286 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.231</td>
###xml 2259 2334 2211 2286 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Antiaggregatory therapy (antiplatelet drugs) <italic>n</italic> (%)</td><td align="left">11 (44)</td><td align="left">7 (70)</td><td align="left">7 (47)</td><td char="." align="char">0.231</td></tr>
###xml 2350 2351 2302 2303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2334 2355 2286 2307 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Beta-blockers, <italic>n</italic> (%)</td>
###xml 2355 2362 2307 2314 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">16 (64)</td>
###xml 2362 2368 2314 2320 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7 (70)</td>
###xml 2368 2375 2320 2327 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">10 (67)</td>
###xml 2375 2380 2327 2332 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.222</td>
###xml 2334 2380 2286 2332 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Beta-blockers, <italic>n</italic> (%)</td><td align="left">16 (64)</td><td align="left">7 (70)</td><td align="left">10 (67)</td><td char="." align="char">0.222</td></tr>
###xml 2401 2402 2353 2354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2380 2406 2332 2358 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;ACE-inhibitors/ARB, <italic>n</italic> (%)</td>
###xml 2406 2413 2358 2365 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">12 (48)</td>
###xml 2413 2419 2365 2371 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6 (60)</td>
###xml 2419 2425 2371 2377 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7 (47)</td>
###xml 2425 2430 2377 2382 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.688</td>
###xml 2380 2430 2332 2382 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;ACE-inhibitors/ARB, <italic>n</italic> (%)</td><td align="left">12 (48)</td><td align="left">6 (60)</td><td align="left">7 (47)</td><td char="." align="char">0.688</td></tr>
###xml 2440 2441 2392 2393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2430 2445 2382 2397 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Statins, <italic>n</italic> (%)</td>
###xml 2445 2452 2397 2404 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">12 (48)</td>
###xml 2452 2458 2404 2410 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">8 (80)</td>
###xml 2458 2465 2410 2417 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">12 (80)</td>
###xml 2465 2470 2417 2422 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.687</td>
###xml 2430 2470 2382 2422 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Statins, <italic>n</italic> (%)</td><td align="left">12 (48)</td><td align="left">8 (80)</td><td align="left">12 (80)</td><td char="." align="char">0.687</td></tr>
###xml 1434 2470 1434 2422 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Age (years)</td><td align="left">59.9&#160;&#177;&#160;12.7</td><td align="left">63.7&#160;&#177;&#160;9.9</td><td align="left">66&#160;&#177;&#160;11</td><td char="." align="char">0.579</td></tr><tr><td align="left">BMI</td><td align="left">ND</td><td align="left">26.8&#160;&#177;&#160;2</td><td align="left">26.3&#160;&#177;&#160;5</td><td align="left"/></tr><tr><td align="left">Male gender, <italic>n</italic> (%)</td><td align="left">12 (48)</td><td align="left">7 (70)</td><td align="left">9 (60)</td><td char="." align="char">0.470</td></tr><tr><td align="left" colspan="5">Cardiovascular risk factors</td></tr><tr><td align="left">&#160;CAD history (years)</td><td align="left">0</td><td align="left">10&#160;&#177;&#160;8</td><td align="left">9&#160;&#177;&#160;8</td><td char="." align="char">0.578</td></tr><tr><td align="left">&#160;Family history of CAD, <italic>n</italic> (%)</td><td align="left">11 (44)</td><td align="left">7 (70)</td><td align="left">7 (47)</td><td char="." align="char">0.231</td></tr><tr><td align="left">&#160;Hypertension, <italic>n</italic> (%)</td><td align="left">12 (48)</td><td align="left">4 (40)</td><td align="left">9 (60)</td><td char="." align="char">0.284</td></tr><tr><td align="left">&#160;Smoking, <italic>n</italic> (%)</td><td align="left">6 (24)</td><td align="left">3 (30)</td><td align="left">6 (40)</td><td char="." align="char">0.607</td></tr><tr><td align="left">&#160;Diabetes, <italic>n</italic> (%)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">15 (100)</td><td align="left"/></tr><tr><td align="left">&#160;Duration of DM (years)</td><td align="left">0</td><td align="left">0</td><td align="left">8&#160;&#177;&#160;7</td><td align="left"/></tr><tr><td align="left">&#160;Patients receiving insulin (%)</td><td align="left">0</td><td align="left">0</td><td align="left">40</td><td align="left"/></tr><tr><td align="left">&#160;Patients receiving OHD (%)</td><td align="left">0</td><td align="left">0</td><td align="left">100</td><td align="left"/></tr><tr><td align="left">&#160;FPG (mmol/l)</td><td align="left">5.5&#160;&#177;&#160;0.7</td><td align="left">6.3&#160;&#177;&#160;0.7</td><td align="left">8.3&#160;&#177;&#160;4.6</td><td char="." align="char">0.048</td></tr><tr><td align="left">&#160;HbA<sub>1c</sub> (%)</td><td align="left">ND</td><td align="left">ND</td><td align="left">7.3&#160;&#177;&#160;0.6</td><td align="left"/></tr><tr><td align="left" colspan="5">Laboratory parameters</td></tr><tr><td align="left">&#160;Cholesterol, total (mmol/l)</td><td align="left">5.9&#160;&#177;&#160;1.3</td><td align="left">4.4&#160;&#177;&#160;0.8</td><td align="left">4.0&#160;&#177;&#160;1.4</td><td char="." align="char">0.283</td></tr><tr><td align="left">&#160;LDL-cholesterol (mmol/l)</td><td align="left">4.0&#160;&#177;&#160;1.2</td><td align="left">2.1&#160;&#177;&#160;0.8</td><td align="left">2.1&#160;&#177;&#160;0.9</td><td char="." align="char">0.16</td></tr><tr><td align="left">&#160;HDL-cholesterol (mmol/l)</td><td align="left">1.8&#160;&#177;&#160;1.0</td><td align="left">1.2&#160;&#177;&#160;0.6</td><td align="left">1.0&#160;&#177;&#160;0.3</td><td char="." align="char">0.127</td></tr><tr><td align="left">&#160;Triglycerides (mmol/l)</td><td align="left">1.8&#160;&#177;&#160;1.2</td><td align="left">1.8&#160;&#177;&#160;0.4</td><td align="left">2.1&#160;&#177;&#160;1.1</td><td char="." align="char">0.638</td></tr><tr><td align="left" colspan="5">Medication at admission</td></tr><tr><td align="left">&#160;Antiaggregatory therapy (antiplatelet drugs) <italic>n</italic> (%)</td><td align="left">11 (44)</td><td align="left">7 (70)</td><td align="left">7 (47)</td><td char="." align="char">0.231</td></tr><tr><td align="left">&#160;Beta-blockers, <italic>n</italic> (%)</td><td align="left">16 (64)</td><td align="left">7 (70)</td><td align="left">10 (67)</td><td char="." align="char">0.222</td></tr><tr><td align="left">&#160;ACE-inhibitors/ARB, <italic>n</italic> (%)</td><td align="left">12 (48)</td><td align="left">6 (60)</td><td align="left">7 (47)</td><td char="." align="char">0.688</td></tr><tr><td align="left">&#160;Statins, <italic>n</italic> (%)</td><td align="left">12 (48)</td><td align="left">8 (80)</td><td align="left">12 (80)</td><td char="." align="char">0.687</td></tr></tbody>
###xml 1388 2470 1388 2422 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">CTR, <italic>n</italic>&#160;=&#160;25</th><th align="left">CAD&#8722;DM, <italic>n</italic>&#160;=&#160;10</th><th align="left">CAD+DM, <italic>n</italic>&#160;=&#160;15</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left">59.9&#160;&#177;&#160;12.7</td><td align="left">63.7&#160;&#177;&#160;9.9</td><td align="left">66&#160;&#177;&#160;11</td><td char="." align="char">0.579</td></tr><tr><td align="left">BMI</td><td align="left">ND</td><td align="left">26.8&#160;&#177;&#160;2</td><td align="left">26.3&#160;&#177;&#160;5</td><td align="left"/></tr><tr><td align="left">Male gender, <italic>n</italic> (%)</td><td align="left">12 (48)</td><td align="left">7 (70)</td><td align="left">9 (60)</td><td char="." align="char">0.470</td></tr><tr><td align="left" colspan="5">Cardiovascular risk factors</td></tr><tr><td align="left">&#160;CAD history (years)</td><td align="left">0</td><td align="left">10&#160;&#177;&#160;8</td><td align="left">9&#160;&#177;&#160;8</td><td char="." align="char">0.578</td></tr><tr><td align="left">&#160;Family history of CAD, <italic>n</italic> (%)</td><td align="left">11 (44)</td><td align="left">7 (70)</td><td align="left">7 (47)</td><td char="." align="char">0.231</td></tr><tr><td align="left">&#160;Hypertension, <italic>n</italic> (%)</td><td align="left">12 (48)</td><td align="left">4 (40)</td><td align="left">9 (60)</td><td char="." align="char">0.284</td></tr><tr><td align="left">&#160;Smoking, <italic>n</italic> (%)</td><td align="left">6 (24)</td><td align="left">3 (30)</td><td align="left">6 (40)</td><td char="." align="char">0.607</td></tr><tr><td align="left">&#160;Diabetes, <italic>n</italic> (%)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">15 (100)</td><td align="left"/></tr><tr><td align="left">&#160;Duration of DM (years)</td><td align="left">0</td><td align="left">0</td><td align="left">8&#160;&#177;&#160;7</td><td align="left"/></tr><tr><td align="left">&#160;Patients receiving insulin (%)</td><td align="left">0</td><td align="left">0</td><td align="left">40</td><td align="left"/></tr><tr><td align="left">&#160;Patients receiving OHD (%)</td><td align="left">0</td><td align="left">0</td><td align="left">100</td><td align="left"/></tr><tr><td align="left">&#160;FPG (mmol/l)</td><td align="left">5.5&#160;&#177;&#160;0.7</td><td align="left">6.3&#160;&#177;&#160;0.7</td><td align="left">8.3&#160;&#177;&#160;4.6</td><td char="." align="char">0.048</td></tr><tr><td align="left">&#160;HbA<sub>1c</sub> (%)</td><td align="left">ND</td><td align="left">ND</td><td align="left">7.3&#160;&#177;&#160;0.6</td><td align="left"/></tr><tr><td align="left" colspan="5">Laboratory parameters</td></tr><tr><td align="left">&#160;Cholesterol, total (mmol/l)</td><td align="left">5.9&#160;&#177;&#160;1.3</td><td align="left">4.4&#160;&#177;&#160;0.8</td><td align="left">4.0&#160;&#177;&#160;1.4</td><td char="." align="char">0.283</td></tr><tr><td align="left">&#160;LDL-cholesterol (mmol/l)</td><td align="left">4.0&#160;&#177;&#160;1.2</td><td align="left">2.1&#160;&#177;&#160;0.8</td><td align="left">2.1&#160;&#177;&#160;0.9</td><td char="." align="char">0.16</td></tr><tr><td align="left">&#160;HDL-cholesterol (mmol/l)</td><td align="left">1.8&#160;&#177;&#160;1.0</td><td align="left">1.2&#160;&#177;&#160;0.6</td><td align="left">1.0&#160;&#177;&#160;0.3</td><td char="." align="char">0.127</td></tr><tr><td align="left">&#160;Triglycerides (mmol/l)</td><td align="left">1.8&#160;&#177;&#160;1.2</td><td align="left">1.8&#160;&#177;&#160;0.4</td><td align="left">2.1&#160;&#177;&#160;1.1</td><td char="." align="char">0.638</td></tr><tr><td align="left" colspan="5">Medication at admission</td></tr><tr><td align="left">&#160;Antiaggregatory therapy (antiplatelet drugs) <italic>n</italic> (%)</td><td align="left">11 (44)</td><td align="left">7 (70)</td><td align="left">7 (47)</td><td char="." align="char">0.231</td></tr><tr><td align="left">&#160;Beta-blockers, <italic>n</italic> (%)</td><td align="left">16 (64)</td><td align="left">7 (70)</td><td align="left">10 (67)</td><td char="." align="char">0.222</td></tr><tr><td align="left">&#160;ACE-inhibitors/ARB, <italic>n</italic> (%)</td><td align="left">12 (48)</td><td align="left">6 (60)</td><td align="left">7 (47)</td><td char="." align="char">0.688</td></tr><tr><td align="left">&#160;Statins, <italic>n</italic> (%)</td><td align="left">12 (48)</td><td align="left">8 (80)</td><td align="left">12 (80)</td><td char="." align="char">0.687</td></tr></tbody></table>
###xml 2512 2513 2462 2463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2470 2554 2422 2504 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="10">Results are expressed as the mean&#160;&#177;&#160;SD. <italic>P</italic> value indicated for CAD&#8722;DM versus CAD+DM</p>
###xml 2554 2557 2504 2507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAD</italic>
###xml 2583 2585 2533 2535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DM</italic>
###xml 2612 2615 2562 2565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 2647 2650 2597 2600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARB</italic>
###xml 2682 2685 2632 2635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FPG</italic>
###xml 2710 2712 2660 2662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ND</italic>
###xml 2729 2732 2679 2682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OHD</italic>
###xml 2554 2756 2504 2706 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="11"><italic>CAD</italic> Coronary artery disease, <italic>DM</italic> type 2 diabetes mellitus, <italic>ACE</italic> angiotensin converting enzyme, <italic>ARB</italic> angiotensin receptor blockers, <italic>FPG</italic> fasting plasma glucose, <italic>ND</italic> not determined, <italic>OHD</italic> oral hypoglycemic drugs</p>
###xml 2470 2756 2422 2706 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="10">Results are expressed as the mean&#160;&#177;&#160;SD. <italic>P</italic> value indicated for CAD&#8722;DM versus CAD+DM</p><p textid="11"><italic>CAD</italic> Coronary artery disease, <italic>DM</italic> type 2 diabetes mellitus, <italic>ACE</italic> angiotensin converting enzyme, <italic>ARB</italic> angiotensin receptor blockers, <italic>FPG</italic> fasting plasma glucose, <italic>ND</italic> not determined, <italic>OHD</italic> oral hypoglycemic drugs</p></table-wrap-foot>
###xml 1324 2756 1324 2706 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="9">Clinical characteristics of control subjects and patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">CTR, <italic>n</italic>&#160;=&#160;25</th><th align="left">CAD&#8722;DM, <italic>n</italic>&#160;=&#160;10</th><th align="left">CAD+DM, <italic>n</italic>&#160;=&#160;15</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left">59.9&#160;&#177;&#160;12.7</td><td align="left">63.7&#160;&#177;&#160;9.9</td><td align="left">66&#160;&#177;&#160;11</td><td char="." align="char">0.579</td></tr><tr><td align="left">BMI</td><td align="left">ND</td><td align="left">26.8&#160;&#177;&#160;2</td><td align="left">26.3&#160;&#177;&#160;5</td><td align="left"/></tr><tr><td align="left">Male gender, <italic>n</italic> (%)</td><td align="left">12 (48)</td><td align="left">7 (70)</td><td align="left">9 (60)</td><td char="." align="char">0.470</td></tr><tr><td align="left" colspan="5">Cardiovascular risk factors</td></tr><tr><td align="left">&#160;CAD history (years)</td><td align="left">0</td><td align="left">10&#160;&#177;&#160;8</td><td align="left">9&#160;&#177;&#160;8</td><td char="." align="char">0.578</td></tr><tr><td align="left">&#160;Family history of CAD, <italic>n</italic> (%)</td><td align="left">11 (44)</td><td align="left">7 (70)</td><td align="left">7 (47)</td><td char="." align="char">0.231</td></tr><tr><td align="left">&#160;Hypertension, <italic>n</italic> (%)</td><td align="left">12 (48)</td><td align="left">4 (40)</td><td align="left">9 (60)</td><td char="." align="char">0.284</td></tr><tr><td align="left">&#160;Smoking, <italic>n</italic> (%)</td><td align="left">6 (24)</td><td align="left">3 (30)</td><td align="left">6 (40)</td><td char="." align="char">0.607</td></tr><tr><td align="left">&#160;Diabetes, <italic>n</italic> (%)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">15 (100)</td><td align="left"/></tr><tr><td align="left">&#160;Duration of DM (years)</td><td align="left">0</td><td align="left">0</td><td align="left">8&#160;&#177;&#160;7</td><td align="left"/></tr><tr><td align="left">&#160;Patients receiving insulin (%)</td><td align="left">0</td><td align="left">0</td><td align="left">40</td><td align="left"/></tr><tr><td align="left">&#160;Patients receiving OHD (%)</td><td align="left">0</td><td align="left">0</td><td align="left">100</td><td align="left"/></tr><tr><td align="left">&#160;FPG (mmol/l)</td><td align="left">5.5&#160;&#177;&#160;0.7</td><td align="left">6.3&#160;&#177;&#160;0.7</td><td align="left">8.3&#160;&#177;&#160;4.6</td><td char="." align="char">0.048</td></tr><tr><td align="left">&#160;HbA<sub>1c</sub> (%)</td><td align="left">ND</td><td align="left">ND</td><td align="left">7.3&#160;&#177;&#160;0.6</td><td align="left"/></tr><tr><td align="left" colspan="5">Laboratory parameters</td></tr><tr><td align="left">&#160;Cholesterol, total (mmol/l)</td><td align="left">5.9&#160;&#177;&#160;1.3</td><td align="left">4.4&#160;&#177;&#160;0.8</td><td align="left">4.0&#160;&#177;&#160;1.4</td><td char="." align="char">0.283</td></tr><tr><td align="left">&#160;LDL-cholesterol (mmol/l)</td><td align="left">4.0&#160;&#177;&#160;1.2</td><td align="left">2.1&#160;&#177;&#160;0.8</td><td align="left">2.1&#160;&#177;&#160;0.9</td><td char="." align="char">0.16</td></tr><tr><td align="left">&#160;HDL-cholesterol (mmol/l)</td><td align="left">1.8&#160;&#177;&#160;1.0</td><td align="left">1.2&#160;&#177;&#160;0.6</td><td align="left">1.0&#160;&#177;&#160;0.3</td><td char="." align="char">0.127</td></tr><tr><td align="left">&#160;Triglycerides (mmol/l)</td><td align="left">1.8&#160;&#177;&#160;1.2</td><td align="left">1.8&#160;&#177;&#160;0.4</td><td align="left">2.1&#160;&#177;&#160;1.1</td><td char="." align="char">0.638</td></tr><tr><td align="left" colspan="5">Medication at admission</td></tr><tr><td align="left">&#160;Antiaggregatory therapy (antiplatelet drugs) <italic>n</italic> (%)</td><td align="left">11 (44)</td><td align="left">7 (70)</td><td align="left">7 (47)</td><td char="." align="char">0.231</td></tr><tr><td align="left">&#160;Beta-blockers, <italic>n</italic> (%)</td><td align="left">16 (64)</td><td align="left">7 (70)</td><td align="left">10 (67)</td><td char="." align="char">0.222</td></tr><tr><td align="left">&#160;ACE-inhibitors/ARB, <italic>n</italic> (%)</td><td align="left">12 (48)</td><td align="left">6 (60)</td><td align="left">7 (47)</td><td char="." align="char">0.688</td></tr><tr><td align="left">&#160;Statins, <italic>n</italic> (%)</td><td align="left">12 (48)</td><td align="left">8 (80)</td><td align="left">12 (80)</td><td char="." align="char">0.687</td></tr></tbody></table><table-wrap-foot><p textid="10">Results are expressed as the mean&#160;&#177;&#160;SD. <italic>P</italic> value indicated for CAD&#8722;DM versus CAD+DM</p><p textid="11"><italic>CAD</italic> Coronary artery disease, <italic>DM</italic> type 2 diabetes mellitus, <italic>ACE</italic> angiotensin converting enzyme, <italic>ARB</italic> angiotensin receptor blockers, <italic>FPG</italic> fasting plasma glucose, <italic>ND</italic> not determined, <italic>OHD</italic> oral hypoglycemic drugs</p></table-wrap-foot></table-wrap>
###xml 309 317 <span type="species:ncbi:9606">Patients</span>
###xml 489 497 <span type="species:ncbi:9606">Patients</span>
###xml 607 615 <span type="species:ncbi:9606">patients</span>
###xml 657 665 <span type="species:ncbi:9606">patients</span>
###xml 1016 1024 <span type="species:ncbi:9606">patients</span>
###xml 1207 1215 <span type="species:ncbi:9606">patients</span>
###xml 1821 1829 <span type="species:ncbi:9606">Patients</span>
###xml 1856 1864 <span type="species:ncbi:9606">Patients</span>
This study was performed with the approval of the medical ethics committee of the University Hospital of Maastricht (The Netherlands), and conforms to the principals outlined in the Declaration of Helsinki. All enrolled subjects gave their written informed consent. Three groups of subjects were studied: (1) Patients with stable coronary artery disease without diabetes mellitus (CAD-DM, n = 10). Stable CAD was defined as history of stable angina pectoris or history of PCI and/or CABG. Patients with acute myocardial infarction and/or recent surgical intervention (less then 6 months) were excluded. All patients had a recent coronary angiogram. (2) CAD patients with diabetes mellitus (CAD+DM, n = 15). The diagnosis of DM was verified by history of DM, elevated fasting glucose level and/or increased concentration of glycosylated HbA1c. (3) Control subjects (CTR) without any history or clinical signs of CAD, metabolic disease or chronic illness (n = 25). Baseline clinical features of CTR, CAD-DM and CAD+DM patients are presented in Table 1. There were no significant differences between three groups with regards to age, gender, BMI, presence of cardiovascular risk factors and medication. CAD+DM patients exhibited higher fasting glucose level compared to CTR (P = 0.019) and compared to CAD-DM group (P = 0.048).Table 1Clinical characteristics of control subjects and patientsCTR, n = 25CAD-DM, n = 10CAD+DM, n = 15P valueAge (years)59.9 +/- 12.763.7 +/- 9.966 +/- 110.579BMIND26.8 +/- 226.3 +/- 5Male gender, n (%)12 (48)7 (70)9 (60)0.470Cardiovascular risk factors CAD history (years)010 +/- 89 +/- 80.578 Family history of CAD, n (%)11 (44)7 (70)7 (47)0.231 Hypertension, n (%)12 (48)4 (40)9 (60)0.284 Smoking, n (%)6 (24)3 (30)6 (40)0.607 Diabetes, n (%)0 (0)0 (0)15 (100) Duration of DM (years)008 +/- 7 Patients receiving insulin (%)0040 Patients receiving OHD (%)00100 FPG (mmol/l)5.5 +/- 0.76.3 +/- 0.78.3 +/- 4.60.048 HbA1c (%)NDND7.3 +/- 0.6Laboratory parameters Cholesterol, total (mmol/l)5.9 +/- 1.34.4 +/- 0.84.0 +/- 1.40.283 LDL-cholesterol (mmol/l)4.0 +/- 1.22.1 +/- 0.82.1 +/- 0.90.16 HDL-cholesterol (mmol/l)1.8 +/- 1.01.2 +/- 0.61.0 +/- 0.30.127 Triglycerides (mmol/l)1.8 +/- 1.21.8 +/- 0.42.1 +/- 1.10.638Medication at admission Antiaggregatory therapy (antiplatelet drugs) n (%)11 (44)7 (70)7 (47)0.231 Beta-blockers, n (%)16 (64)7 (70)10 (67)0.222 ACE-inhibitors/ARB, n (%)12 (48)6 (60)7 (47)0.688 Statins, n (%)12 (48)8 (80)12 (80)0.687Results are expressed as the mean +/- SD. P value indicated for CAD-DM versus CAD+DMCAD Coronary artery disease, DM type 2 diabetes mellitus, ACE angiotensin converting enzyme, ARB angiotensin receptor blockers, FPG fasting plasma glucose, ND not determined, OHD oral hypoglycemic drugs
###end p 8
###begin p 9
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of control subjects and patients
###end p 9
###begin p 10
###xml 42 43 40 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Results are expressed as the mean +/- SD. P value indicated for CAD-DM versus CAD+DM
###end p 10
###begin p 11
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAD</italic>
###xml 29 31 29 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DM</italic>
###xml 58 61 58 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 93 96 93 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARB</italic>
###xml 128 131 128 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FPG</italic>
###xml 156 158 156 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ND</italic>
###xml 175 178 175 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OHD</italic>
CAD Coronary artery disease, DM type 2 diabetes mellitus, ACE angiotensin converting enzyme, ARB angiotensin receptor blockers, FPG fasting plasma glucose, ND not determined, OHD oral hypoglycemic drugs
###end p 11
###begin title 12
Monocyte isolation and migration
###end title 12
###begin p 13
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 320 321 318 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 589 590 580 581 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1248 1251 1233 1236 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i/o</sub>
Blood samples (100 ml) were collected from all subjects. Monocytes were isolated by Percoll gradient centrifugation based on a previously described protocol [40]. The purity of isolated monocytes was >/=90% as determined by flow cytometry. Monocytes were subjected to chemotaxis assay using the modified Boyden chamber [2]. Briefly, different concentrations of Shh or Ihh were placed in the bottom well and monocytes were placed in the top well. Polycarbonate membranes with a pore diameter of 5 mum (Nuclepore) were used. The chambers were incubated at 37degreesC in the presence of 5% CO2 for 90 min. Afterwards filters were removed, fixed, stained with Giemsa dye before scraping off cells at the upper side of the filter membrane and five high-power fields were counted for each sample (primary magnification 20x). To differentiate between chemotaxis and chemokinesis, checkerboard analysis was performed by placing various dilutions of Shh in both the lower and upper wells of the modified Boyden chamber. To study the effect of different inhibitors on Shh-induced migration, monocytes were pretreated with a specific inhibitor of Hh signaling, cyclopamine (CP, 10 muM), the PI3K inhibitor, LY294002 (10 muM), or a specific inhibitor of Galphai/o, pertussis toxin (PTX, 100 ng/ml) for 15 min before the chemotaxis assay.
###end p 13
###begin title 14
RT-PCR analysis
###end title 14
###begin p 15
###xml 330 331 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 332 339 324 331 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 339 377 331 369 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="16">Primers and conditions used for RT-PCR</p>
###xml 339 377 331 369 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="16">Primers and conditions used for RT-PCR</p></caption>
###xml 377 381 369 373 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Gene</th>
###xml 381 397 373 389 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Sequence (5&#8242;&#8211;3&#8242;)</th>
###xml 397 435 389 427 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Annealing temperature and cycle number</th>
###xml 435 453 427 445 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fragment size (bp)</th>
###xml 377 453 369 445 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Gene</th><th align="left">Sequence (5&#8242;&#8211;3&#8242;)</th><th align="left">Annealing temperature and cycle number</th><th align="left">Fragment size (bp)</th></tr>
###xml 377 453 369 445 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Gene</th><th align="left">Sequence (5&#8242;&#8211;3&#8242;)</th><th align="left">Annealing temperature and cycle number</th><th align="left">Fragment size (bp)</th></tr></thead>
###xml 453 456 445 448 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Shh</td>
###xml 456 491 448 483 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FW: ACT GGG TGT ACT ACG AGT CCA AGG</td>
###xml 491 512 483 498 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">63&#176;C, 50 cycles</td>
###xml 512 515 498 501 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">211</td>
###xml 453 515 445 501 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="2">Shh</td><td align="left">FW: ACT GGG TGT ACT ACG AGT CCA AGG</td><td align="left" rowspan="2">63&#176;C, 50 cycles</td><td align="left" rowspan="2">211</td></tr>
###xml 515 550 501 536 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RV: AAA GTG AGG AAG TCG CTG TAG AGC</td>
###xml 515 550 501 536 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">RV: AAA GTG AGG AAG TCG CTG TAG AGC</td></tr>
###xml 550 553 536 539 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Ihh</td>
###xml 553 582 539 568 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FW: CTA CGC CCC GCT CAC AAA G</td>
###xml 582 603 568 583 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">60&#176;C, 30 cycles</td>
###xml 603 606 583 586 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">376</td>
###xml 550 606 536 586 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="2">Ihh</td><td align="left">FW: CTA CGC CCC GCT CAC AAA G</td><td align="left" rowspan="2">60&#176;C, 30 cycles</td><td align="left" rowspan="2">376</td></tr>
###xml 606 636 586 616 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RV: GGC AGA GGA GAT GGC AGG AG</td>
###xml 606 636 586 616 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">RV: GGC AGA GGA GAT GGC AGG AG</td></tr>
###xml 636 639 616 619 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Dhh</td>
###xml 639 663 619 643 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FW: ACCAATCTACTGCCCCTGTG</td>
###xml 663 684 643 658 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">62&#176;C, 30 cycles</td>
###xml 684 687 658 661 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">246</td>
###xml 636 687 616 661 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="2">Dhh</td><td align="left">FW: ACCAATCTACTGCCCCTGTG</td><td align="left" rowspan="2">62&#176;C, 30 cycles</td><td align="left" rowspan="2">246</td></tr>
###xml 687 711 661 685 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RV: GTTGTAGTTGGGCACGAGGT</td>
###xml 687 711 661 685 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">RV: GTTGTAGTTGGGCACGAGGT</td></tr>
###xml 711 714 685 688 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Smo</td>
###xml 714 747 688 721 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FW: CAG GAC ATG CAC AGC TAC ATC G</td>
###xml 747 768 721 736 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">65&#176;C, 30 cycles</td>
###xml 768 771 736 739 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">380</td>
###xml 711 771 685 739 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="2">Smo</td><td align="left">FW: CAG GAC ATG CAC AGC TAC ATC G</td><td align="left" rowspan="2">65&#176;C, 30 cycles</td><td align="left" rowspan="2">380</td></tr>
###xml 771 804 739 772 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RV: CCA CAA AGA AGC ACG CAT TGA C</td>
###xml 771 804 739 772 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">RV: CCA CAA AGA AGC ACG CAT TGA C</td></tr>
###xml 804 807 772 775 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Ptc</td>
###xml 807 838 775 806 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FW: CCA TGT TCC AGT TAA TGA CTC</td>
###xml 838 859 806 821 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">55&#176;C, 30 cycles</td>
###xml 859 862 821 824 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">462</td>
###xml 804 862 772 824 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="2">Ptc</td><td align="left">FW: CCA TGT TCC AGT TAA TGA CTC</td><td align="left" rowspan="2">55&#176;C, 30 cycles</td><td align="left" rowspan="2">462</td></tr>
###xml 862 889 824 851 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RV: ACA TCA TCC ACA CCA ACA</td>
###xml 862 889 824 851 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">RV: ACA TCA TCC ACA CCA ACA</td></tr>
###xml 889 893 851 855 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">SUFU</td>
###xml 893 923 855 885 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FW: CCT CCA GAT CGT TGG TGT CT</td>
###xml 923 944 885 900 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">55&#176;C, 30 cycles</td>
###xml 944 947 900 903 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">195</td>
###xml 889 947 851 903 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="2">SUFU</td><td align="left">FW: CCT CCA GAT CGT TGG TGT CT</td><td align="left" rowspan="2">55&#176;C, 30 cycles</td><td align="left" rowspan="2">195</td></tr>
###xml 947 977 903 933 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RV: CTG TCT CGA TGC CTT TGT CA</td>
###xml 947 977 903 933 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">RV: CTG TCT CGA TGC CTT TGT CA</td></tr>
###xml 977 982 933 938 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Gli-1</td>
###xml 982 1016 938 972 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FW: GGG ATG ATC CCA CAT CCT CAG TC</td>
###xml 1016 1037 972 987 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">60&#176;C, 50 cycles</td>
###xml 1037 1040 987 990 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">386</td>
###xml 977 1040 933 990 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="2">Gli-1</td><td align="left">FW: GGG ATG ATC CCA CAT CCT CAG TC</td><td align="left" rowspan="2">60&#176;C, 50 cycles</td><td align="left" rowspan="2">386</td></tr>
###xml 1040 1069 990 1019 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RV: CTG GAG CAG CCC CCC CAG T</td>
###xml 1040 1069 990 1019 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">RV: CTG GAG CAG CCC CCC CAG T</td></tr>
###xml 1069 1074 1019 1024 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Gli-2</td>
###xml 1074 1104 1024 1054 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FW: ACC GCT GCT CAA AGA GAA TG</td>
###xml 1104 1125 1054 1069 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">64&#176;C, 50 cycles</td>
###xml 1125 1128 1069 1072 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">507</td>
###xml 1069 1128 1019 1072 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="2">Gli-2</td><td align="left">FW: ACC GCT GCT CAA AGA GAA TG</td><td align="left" rowspan="2">64&#176;C, 50 cycles</td><td align="left" rowspan="2">507</td></tr>
###xml 1128 1161 1072 1105 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RV: CCC ACT GCC ACT GAA GTT TTC C</td>
###xml 1128 1161 1072 1105 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">RV: CCC ACT GCC ACT GAA GTT TTC C</td></tr>
###xml 1161 1165 1105 1109 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Gli3</td>
###xml 1165 1195 1109 1139 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FW: CCT CAA AGC GGG CCG CCT GC</td>
###xml 1195 1216 1139 1154 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">64&#176;C, 50 cycles</td>
###xml 1216 1219 1154 1157 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">406</td>
###xml 1161 1219 1105 1157 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="2">Gli3</td><td align="left">FW: CCT CAA AGC GGG CCG CCT GC</td><td align="left" rowspan="2">64&#176;C, 50 cycles</td><td align="left" rowspan="2">406</td></tr>
###xml 1219 1253 1157 1191 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RV: CAG GTT GTT GTT GGA CTG TGT GC</td>
###xml 1219 1253 1157 1191 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">RV: CAG GTT GTT GTT GGA CTG TGT GC</td></tr>
###xml 453 1253 445 1191 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" rowspan="2">Shh</td><td align="left">FW: ACT GGG TGT ACT ACG AGT CCA AGG</td><td align="left" rowspan="2">63&#176;C, 50 cycles</td><td align="left" rowspan="2">211</td></tr><tr><td align="left">RV: AAA GTG AGG AAG TCG CTG TAG AGC</td></tr><tr><td align="left" rowspan="2">Ihh</td><td align="left">FW: CTA CGC CCC GCT CAC AAA G</td><td align="left" rowspan="2">60&#176;C, 30 cycles</td><td align="left" rowspan="2">376</td></tr><tr><td align="left">RV: GGC AGA GGA GAT GGC AGG AG</td></tr><tr><td align="left" rowspan="2">Dhh</td><td align="left">FW: ACCAATCTACTGCCCCTGTG</td><td align="left" rowspan="2">62&#176;C, 30 cycles</td><td align="left" rowspan="2">246</td></tr><tr><td align="left">RV: GTTGTAGTTGGGCACGAGGT</td></tr><tr><td align="left" rowspan="2">Smo</td><td align="left">FW: CAG GAC ATG CAC AGC TAC ATC G</td><td align="left" rowspan="2">65&#176;C, 30 cycles</td><td align="left" rowspan="2">380</td></tr><tr><td align="left">RV: CCA CAA AGA AGC ACG CAT TGA C</td></tr><tr><td align="left" rowspan="2">Ptc</td><td align="left">FW: CCA TGT TCC AGT TAA TGA CTC</td><td align="left" rowspan="2">55&#176;C, 30 cycles</td><td align="left" rowspan="2">462</td></tr><tr><td align="left">RV: ACA TCA TCC ACA CCA ACA</td></tr><tr><td align="left" rowspan="2">SUFU</td><td align="left">FW: CCT CCA GAT CGT TGG TGT CT</td><td align="left" rowspan="2">55&#176;C, 30 cycles</td><td align="left" rowspan="2">195</td></tr><tr><td align="left">RV: CTG TCT CGA TGC CTT TGT CA</td></tr><tr><td align="left" rowspan="2">Gli-1</td><td align="left">FW: GGG ATG ATC CCA CAT CCT CAG TC</td><td align="left" rowspan="2">60&#176;C, 50 cycles</td><td align="left" rowspan="2">386</td></tr><tr><td align="left">RV: CTG GAG CAG CCC CCC CAG T</td></tr><tr><td align="left" rowspan="2">Gli-2</td><td align="left">FW: ACC GCT GCT CAA AGA GAA TG</td><td align="left" rowspan="2">64&#176;C, 50 cycles</td><td align="left" rowspan="2">507</td></tr><tr><td align="left">RV: CCC ACT GCC ACT GAA GTT TTC C</td></tr><tr><td align="left" rowspan="2">Gli3</td><td align="left">FW: CCT CAA AGC GGG CCG CCT GC</td><td align="left" rowspan="2">64&#176;C, 50 cycles</td><td align="left" rowspan="2">406</td></tr><tr><td align="left">RV: CAG GTT GTT GTT GGA CTG TGT GC</td></tr></tbody>
###xml 377 1253 369 1191 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Gene</th><th align="left">Sequence (5&#8242;&#8211;3&#8242;)</th><th align="left">Annealing temperature and cycle number</th><th align="left">Fragment size (bp)</th></tr></thead><tbody><tr><td align="left" rowspan="2">Shh</td><td align="left">FW: ACT GGG TGT ACT ACG AGT CCA AGG</td><td align="left" rowspan="2">63&#176;C, 50 cycles</td><td align="left" rowspan="2">211</td></tr><tr><td align="left">RV: AAA GTG AGG AAG TCG CTG TAG AGC</td></tr><tr><td align="left" rowspan="2">Ihh</td><td align="left">FW: CTA CGC CCC GCT CAC AAA G</td><td align="left" rowspan="2">60&#176;C, 30 cycles</td><td align="left" rowspan="2">376</td></tr><tr><td align="left">RV: GGC AGA GGA GAT GGC AGG AG</td></tr><tr><td align="left" rowspan="2">Dhh</td><td align="left">FW: ACCAATCTACTGCCCCTGTG</td><td align="left" rowspan="2">62&#176;C, 30 cycles</td><td align="left" rowspan="2">246</td></tr><tr><td align="left">RV: GTTGTAGTTGGGCACGAGGT</td></tr><tr><td align="left" rowspan="2">Smo</td><td align="left">FW: CAG GAC ATG CAC AGC TAC ATC G</td><td align="left" rowspan="2">65&#176;C, 30 cycles</td><td align="left" rowspan="2">380</td></tr><tr><td align="left">RV: CCA CAA AGA AGC ACG CAT TGA C</td></tr><tr><td align="left" rowspan="2">Ptc</td><td align="left">FW: CCA TGT TCC AGT TAA TGA CTC</td><td align="left" rowspan="2">55&#176;C, 30 cycles</td><td align="left" rowspan="2">462</td></tr><tr><td align="left">RV: ACA TCA TCC ACA CCA ACA</td></tr><tr><td align="left" rowspan="2">SUFU</td><td align="left">FW: CCT CCA GAT CGT TGG TGT CT</td><td align="left" rowspan="2">55&#176;C, 30 cycles</td><td align="left" rowspan="2">195</td></tr><tr><td align="left">RV: CTG TCT CGA TGC CTT TGT CA</td></tr><tr><td align="left" rowspan="2">Gli-1</td><td align="left">FW: GGG ATG ATC CCA CAT CCT CAG TC</td><td align="left" rowspan="2">60&#176;C, 50 cycles</td><td align="left" rowspan="2">386</td></tr><tr><td align="left">RV: CTG GAG CAG CCC CCC CAG T</td></tr><tr><td align="left" rowspan="2">Gli-2</td><td align="left">FW: ACC GCT GCT CAA AGA GAA TG</td><td align="left" rowspan="2">64&#176;C, 50 cycles</td><td align="left" rowspan="2">507</td></tr><tr><td align="left">RV: CCC ACT GCC ACT GAA GTT TTC C</td></tr><tr><td align="left" rowspan="2">Gli3</td><td align="left">FW: CCT CAA AGC GGG CCG CCT GC</td><td align="left" rowspan="2">64&#176;C, 50 cycles</td><td align="left" rowspan="2">406</td></tr><tr><td align="left">RV: CAG GTT GTT GTT GGA CTG TGT GC</td></tr></tbody></table>
###xml 332 1253 324 1191 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="16">Primers and conditions used for RT-PCR</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Gene</th><th align="left">Sequence (5&#8242;&#8211;3&#8242;)</th><th align="left">Annealing temperature and cycle number</th><th align="left">Fragment size (bp)</th></tr></thead><tbody><tr><td align="left" rowspan="2">Shh</td><td align="left">FW: ACT GGG TGT ACT ACG AGT CCA AGG</td><td align="left" rowspan="2">63&#176;C, 50 cycles</td><td align="left" rowspan="2">211</td></tr><tr><td align="left">RV: AAA GTG AGG AAG TCG CTG TAG AGC</td></tr><tr><td align="left" rowspan="2">Ihh</td><td align="left">FW: CTA CGC CCC GCT CAC AAA G</td><td align="left" rowspan="2">60&#176;C, 30 cycles</td><td align="left" rowspan="2">376</td></tr><tr><td align="left">RV: GGC AGA GGA GAT GGC AGG AG</td></tr><tr><td align="left" rowspan="2">Dhh</td><td align="left">FW: ACCAATCTACTGCCCCTGTG</td><td align="left" rowspan="2">62&#176;C, 30 cycles</td><td align="left" rowspan="2">246</td></tr><tr><td align="left">RV: GTTGTAGTTGGGCACGAGGT</td></tr><tr><td align="left" rowspan="2">Smo</td><td align="left">FW: CAG GAC ATG CAC AGC TAC ATC G</td><td align="left" rowspan="2">65&#176;C, 30 cycles</td><td align="left" rowspan="2">380</td></tr><tr><td align="left">RV: CCA CAA AGA AGC ACG CAT TGA C</td></tr><tr><td align="left" rowspan="2">Ptc</td><td align="left">FW: CCA TGT TCC AGT TAA TGA CTC</td><td align="left" rowspan="2">55&#176;C, 30 cycles</td><td align="left" rowspan="2">462</td></tr><tr><td align="left">RV: ACA TCA TCC ACA CCA ACA</td></tr><tr><td align="left" rowspan="2">SUFU</td><td align="left">FW: CCT CCA GAT CGT TGG TGT CT</td><td align="left" rowspan="2">55&#176;C, 30 cycles</td><td align="left" rowspan="2">195</td></tr><tr><td align="left">RV: CTG TCT CGA TGC CTT TGT CA</td></tr><tr><td align="left" rowspan="2">Gli-1</td><td align="left">FW: GGG ATG ATC CCA CAT CCT CAG TC</td><td align="left" rowspan="2">60&#176;C, 50 cycles</td><td align="left" rowspan="2">386</td></tr><tr><td align="left">RV: CTG GAG CAG CCC CCC CAG T</td></tr><tr><td align="left" rowspan="2">Gli-2</td><td align="left">FW: ACC GCT GCT CAA AGA GAA TG</td><td align="left" rowspan="2">64&#176;C, 50 cycles</td><td align="left" rowspan="2">507</td></tr><tr><td align="left">RV: CCC ACT GCC ACT GAA GTT TTC C</td></tr><tr><td align="left" rowspan="2">Gli3</td><td align="left">FW: CCT CAA AGC GGG CCG CCT GC</td><td align="left" rowspan="2">64&#176;C, 50 cycles</td><td align="left" rowspan="2">406</td></tr><tr><td align="left">RV: CAG GTT GTT GTT GGA CTG TGT GC</td></tr></tbody></table></table-wrap>
###xml 183 186 <span type="species:ncbi:11866?0.5863095238095238|species:ncbi:12321?0.21726190476190477">AMV</span>
Total RNA from monocytes or HUVEC (used as a control) was isolated using RNeasy Protect Mini Kit from QIAGEN. For reverse transcription, 1 mug of total RNA was converted into cDNA by AMV reverse transcriptase at 37degreesC for 1 h in a 20 mul RT reaction. All the primers used in this study and PCR conditions are listed in Table 2.Table 2Primers and conditions used for RT-PCRGeneSequence (5'-3')Annealing temperature and cycle numberFragment size (bp)ShhFW: ACT GGG TGT ACT ACG AGT CCA AGG63degreesC, 50 cycles211RV: AAA GTG AGG AAG TCG CTG TAG AGCIhhFW: CTA CGC CCC GCT CAC AAA G60degreesC, 30 cycles376RV: GGC AGA GGA GAT GGC AGG AGDhhFW: ACCAATCTACTGCCCCTGTG62degreesC, 30 cycles246RV: GTTGTAGTTGGGCACGAGGTSmoFW: CAG GAC ATG CAC AGC TAC ATC G65degreesC, 30 cycles380RV: CCA CAA AGA AGC ACG CAT TGA CPtcFW: CCA TGT TCC AGT TAA TGA CTC55degreesC, 30 cycles462RV: ACA TCA TCC ACA CCA ACASUFUFW: CCT CCA GAT CGT TGG TGT CT55degreesC, 30 cycles195RV: CTG TCT CGA TGC CTT TGT CAGli-1FW: GGG ATG ATC CCA CAT CCT CAG TC60degreesC, 50 cycles386RV: CTG GAG CAG CCC CCC CAG TGli-2FW: ACC GCT GCT CAA AGA GAA TG64degreesC, 50 cycles507RV: CCC ACT GCC ACT GAA GTT TTC CGli3FW: CCT CAA AGC GGG CCG CCT GC64degreesC, 50 cycles406RV: CAG GTT GTT GTT GGA CTG TGT GC
###end p 15
###begin p 16
Primers and conditions used for RT-PCR
###end p 16
###begin title 17
Flow cytometry analysis
###end title 17
###begin p 18
###xml 212 216 <span type="species:ncbi:9925">goat</span>
Expression of Ptc on leukocytes was analyzed by flow cytometry. Leukocytes were stained with anti-Ptc primary antibodies (Santa Cruz Biotechnology). Double staining with CD14-FITC (Becton Dickinson) and Ptc/anti-goat-PE antibody was performed to confirm the expression of both proteins on monocytes. The analysis was carried out on a FACSCalibur flow cytometer using the CellQuest software (Becton Dickinson).
###end p 18
###begin title 19
Immunohistochemistry
###end title 19
###begin p 20
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 170 175 <span type="species:ncbi:9796">horse</span>
###xml 262 266 <span type="species:ncbi:9925">goat</span>
###xml 326 331 <span type="species:ncbi:10090">mouse</span>
###xml 376 381 <span type="species:ncbi:9796">horse</span>
###xml 387 392 <span type="species:ncbi:10090">mouse</span>
###xml 402 406 <span type="species:ncbi:9925">goat</span>
Cross sections of human aortic atherosclerotic plaque were deparaffinized, dehydrated, and permeabilized with 0.05% Tween in citrate buffer, and then blocked with normal horse serum. Further, they were incubated with primary polyclonal antibodies for Ptc (1:25, goat polyclonals; Santa Cruz Biotechnology Inc) or CD68 (1:100, mouse monoclonal; DakoCytomation). A biotinylated horse anti-mouse and anti-goat IgG (1:1,000) was incubated followed by incubation with streptavidin/HRP antibodies and visualized with AEC staining solution. Consecutive sections were stained and the results of Ptc staining and CD68 staining were merged for demonstration of coexpression. The negative controls included substitution of primary antiserum for PBS.
###end p 20
###begin title 21
Statistical analysis
###end title 21
###begin p 22
###xml 475 476 473 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 520 521 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
###xml 431 439 <span type="species:ncbi:9606">patients</span>
Statistical analysis was performed with SPSS12.0.1 statistical software. Categorical variables are presented as percentage of patients and compared by Fisher's exact test. Data are presented as the mean +/- standard deviation (SD). In addition, the medians (in the figure: median as line, 25th-75th percentiles as box, 5th-95th percentiles as whiskers) are given in case of non-normally distributed results. CTR, CAD-DM and CAD+DM patients were compared using a Mann-Whitney U test with Bonferroni correction. Values of P < 0.05 were considered statistically significant.
###end p 22
###begin title 23
Results
###end title 23
###begin title 24
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human peripheral monocytes express components of Hh signaling
###end title 24
###begin p 25
###xml 569 570 569 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 573 579 573 579 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 643 644 643 644 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 883 884 883 884 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 942 952 942 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Left panel</italic>
###xml 981 992 981 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Right panel</italic>
###xml 579 1102 579 1102 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="26">Expression of Hedgehog signaling components in human monocytes. <bold>a</bold> RT-PCR analysis of the Shh, Ihh, Dhh, Smo, Ptc, SUFU, Hip, Gli1, Gli2, Gli3, and actin gene expression on human peripheral monocytes and HUVEC (used as a positive control). The results are representative of three independent experiments. <bold>b</bold> Flow cytometric analysis of Ptc expression on monocytes. <italic>Left panel</italic> Isotype (negative) control. <italic>Right panel</italic> Purified monocytes were double-stained with anti-Ptc antibodies and CD14 antibodies as a marker for monocytes</p>
###xml 579 1102 579 1102 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="26">Expression of Hedgehog signaling components in human monocytes. <bold>a</bold> RT-PCR analysis of the Shh, Ihh, Dhh, Smo, Ptc, SUFU, Hip, Gli1, Gli2, Gli3, and actin gene expression on human peripheral monocytes and HUVEC (used as a positive control). The results are representative of three independent experiments. <bold>b</bold> Flow cytometric analysis of Ptc expression on monocytes. <italic>Left panel</italic> Isotype (negative) control. <italic>Right panel</italic> Purified monocytes were double-stained with anti-Ptc antibodies and CD14 antibodies as a marker for monocytes</p></caption>
###xml 1102 1102 1102 1102 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="395_2009_47_Fig1_HTML" id="MO1"/>
###xml 573 1102 573 1102 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="26">Expression of Hedgehog signaling components in human monocytes. <bold>a</bold> RT-PCR analysis of the Shh, Ihh, Dhh, Smo, Ptc, SUFU, Hip, Gli1, Gli2, Gli3, and actin gene expression on human peripheral monocytes and HUVEC (used as a positive control). The results are representative of three independent experiments. <bold>b</bold> Flow cytometric analysis of Ptc expression on monocytes. <italic>Left panel</italic> Isotype (negative) control. <italic>Right panel</italic> Purified monocytes were double-stained with anti-Ptc antibodies and CD14 antibodies as a marker for monocytes</p></caption><graphic position="anchor" xlink:href="395_2009_47_Fig1_HTML" id="MO1"/></fig>
###xml 23 28 <span type="species:ncbi:9606">human</span>
###xml 340 345 <span type="species:ncbi:9606">human</span>
###xml 626 631 <span type="species:ncbi:9606">human</span>
###xml 751 756 <span type="species:ncbi:9606">human</span>
Initially, we examined human monocytes for the expression of components involved in Hh signaling including the ligands Shh, Dhh and Ihh, the receptor Ptc, co-receptor Smoothened (Smo), hedgehog interacting protein (Hip), suppressor of Fused (SUFU), transcription factors Gli 1, 2 and 3. We carried out RT-PCR on RNAs prepared from isolated human peripheral monocytes. RNA from HUVEC was used as a positive control. We confirmed the expression of Ihh, Dhh, Ptc, Smo, SUFU and Gli3 genes on monocytes, but could not detect the expression of Shh, Hip, Gli1 and Gli2 (Fig. 1a).Fig. 1Expression of Hedgehog signaling components in human monocytes. a RT-PCR analysis of the Shh, Ihh, Dhh, Smo, Ptc, SUFU, Hip, Gli1, Gli2, Gli3, and actin gene expression on human peripheral monocytes and HUVEC (used as a positive control). The results are representative of three independent experiments. b Flow cytometric analysis of Ptc expression on monocytes. Left panel Isotype (negative) control. Right panel Purified monocytes were double-stained with anti-Ptc antibodies and CD14 antibodies as a marker for monocytes
###end p 25
###begin p 26
###xml 64 65 64 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 304 305 304 305 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 363 373 363 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Left panel</italic>
###xml 402 413 402 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Right panel</italic>
###xml 47 52 <span type="species:ncbi:9606">human</span>
###xml 172 177 <span type="species:ncbi:9606">human</span>
Expression of Hedgehog signaling components in human monocytes. a RT-PCR analysis of the Shh, Ihh, Dhh, Smo, Ptc, SUFU, Hip, Gli1, Gli2, Gli3, and actin gene expression on human peripheral monocytes and HUVEC (used as a positive control). The results are representative of three independent experiments. b Flow cytometric analysis of Ptc expression on monocytes. Left panel Isotype (negative) control. Right panel Purified monocytes were double-stained with anti-Ptc antibodies and CD14 antibodies as a marker for monocytes
###end p 26
###begin p 27
###xml 259 260 259 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
To confirm the surface expression of Hh receptor Ptc protein, flow cytometric analysis was performed. Double staining of the monocyte fraction with the monocyte marker CD14 and Ptc antibodies demonstrated that 95% of the monocytes were positive for Ptc (Fig. 1b). These results suggest that monocytes can be susceptible to Hh protein stimulation.
###end p 27
###begin title 28
Chemotactic properties of Shh
###end title 28
###begin p 29
###xml 257 258 254 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 323 324 317 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 406 407 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 455 456 443 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 472 473 460 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 647 648 634 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 844 845 830 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 942 948 928 934 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 958 959 944 945 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 970 971 956 957 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1110 1111 1096 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1342 1343 1328 1329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1397 1398 1383 1384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1410 1411 1394 1395 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1448 1453 1432 1437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 1467 1471 1451 1455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 948 1640 934 1623 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Both Shh (<bold>a</bold>) and Ihh (<bold>b</bold>) induce migration of human monocytes ex vivo in a concentration-dependent fashion. Monocytes were isolated from peripheral blood samples (<italic>n</italic>&#160;=&#160;25) and the chemotactic response was measured using a modified Boyden chamber. Five high-power fields were counted for each sample (primary magnification &#215;20). Statistical significance was evaluated using the unpaired Student&#8217;s <italic>t</italic> test. The median values are plotted on the graphs. * <italic>P</italic>&#160;&#8804;&#160;0.005. <bold>c</bold> Monocyte migration in the presence (<italic>right</italic>) or absence (<italic>left</italic>) of Shh (1&#160;&#956;g/ml). The representative photograph of the stained filter; monocytes are detected on the lower surface of the filter following migration through the pores</p>
###xml 948 1640 934 1623 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">Both Shh (<bold>a</bold>) and Ihh (<bold>b</bold>) induce migration of human monocytes ex vivo in a concentration-dependent fashion. Monocytes were isolated from peripheral blood samples (<italic>n</italic>&#160;=&#160;25) and the chemotactic response was measured using a modified Boyden chamber. Five high-power fields were counted for each sample (primary magnification &#215;20). Statistical significance was evaluated using the unpaired Student&#8217;s <italic>t</italic> test. The median values are plotted on the graphs. * <italic>P</italic>&#160;&#8804;&#160;0.005. <bold>c</bold> Monocyte migration in the presence (<italic>right</italic>) or absence (<italic>left</italic>) of Shh (1&#160;&#956;g/ml). The representative photograph of the stained filter; monocytes are detected on the lower surface of the filter following migration through the pores</p></caption>
###xml 1640 1640 1623 1623 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="395_2009_47_Fig2_HTML" id="MO2"/>
###xml 942 1640 928 1623 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="30">Both Shh (<bold>a</bold>) and Ihh (<bold>b</bold>) induce migration of human monocytes ex vivo in a concentration-dependent fashion. Monocytes were isolated from peripheral blood samples (<italic>n</italic>&#160;=&#160;25) and the chemotactic response was measured using a modified Boyden chamber. Five high-power fields were counted for each sample (primary magnification &#215;20). Statistical significance was evaluated using the unpaired Student&#8217;s <italic>t</italic> test. The median values are plotted on the graphs. * <italic>P</italic>&#160;&#8804;&#160;0.005. <bold>c</bold> Monocyte migration in the presence (<italic>right</italic>) or absence (<italic>left</italic>) of Shh (1&#160;&#956;g/ml). The representative photograph of the stained filter; monocytes are detected on the lower surface of the filter following migration through the pores</p></caption><graphic position="anchor" xlink:href="395_2009_47_Fig2_HTML" id="MO2"/></fig>
###xml 993 998 <span type="species:ncbi:9606">human</span>
Monocytes isolated from the blood of control subjects were assessed for their ability to migrate to Shh. Shh-induced monocyte chemotaxis with a bell-shaped dose-response curve, whereby stimulation with 0.01 mug/ml Shh stimulated migration to 123.8 +/- 34% (P = 0.622), stimulation with 0.1 mug/ml Shh led to 132.4 +/- 26% (P = 0.093), while stimulation with 1 mug/ml resulted in 172.5 +/- 90% of baseline (P < 0.005), and 2.5 mug/ml Shh in 153.1 +/- 60% (P = 0.006) (Fig. 2a, c). Based on these results, we used 1 mug/ml Shh for all further experiments presented. Similar results were observed when Ihh was used to induce monocyte migration (Fig. 2B). However, the optimal concentration for Ihh was 2.5 mug/ml. In the checkerboard control experiment, when Shh was added to both upper and lower wells, monocyte chemotaxis was not observed (Fig. 2a). These data indicate that a concentration gradient of Shh is required for monocyte chemotaxis.Fig. 2Both Shh (a) and Ihh (b) induce migration of human monocytes ex vivo in a concentration-dependent fashion. Monocytes were isolated from peripheral blood samples (n = 25) and the chemotactic response was measured using a modified Boyden chamber. Five high-power fields were counted for each sample (primary magnification x20). Statistical significance was evaluated using the unpaired Student's t test. The median values are plotted on the graphs. * P </= 0.005. c Monocyte migration in the presence (right) or absence (left) of Shh (1 mug/ml). The representative photograph of the stained filter; monocytes are detected on the lower surface of the filter following migration through the pores
###end p 29
###begin p 30
###xml 10 11 10 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 22 23 22 23 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 162 163 162 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 394 395 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 449 450 449 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 462 463 460 461 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 500 505 498 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 519 523 517 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 45 50 <span type="species:ncbi:9606">human</span>
Both Shh (a) and Ihh (b) induce migration of human monocytes ex vivo in a concentration-dependent fashion. Monocytes were isolated from peripheral blood samples (n = 25) and the chemotactic response was measured using a modified Boyden chamber. Five high-power fields were counted for each sample (primary magnification x20). Statistical significance was evaluated using the unpaired Student's t test. The median values are plotted on the graphs. * P </= 0.005. c Monocyte migration in the presence (right) or absence (left) of Shh (1 mug/ml). The representative photograph of the stained filter; monocytes are detected on the lower surface of the filter following migration through the pores
###end p 30
###begin p 31
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 413 414 413 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 595 601 595 601 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 601 602 601 602 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 616 618 616 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CP</italic>
###xml 875 876 873 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 930 931 928 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 941 942 939 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 955 956 953 954 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 983 984 981 982 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1023 1024 1020 1021 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1138 1139 1134 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1149 1150 1145 1146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 601 1155 601 1151 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32"><bold>a</bold> Cyclopamine (<italic>CP</italic>) inhibits Shh-induced monocyte chemotaxis. Monocytes were pretreated with CP (10&#160;&#956;M) for 15&#160;min and chemotactic response to Shh (1&#160;&#956;g/ml) was measured using the modified Boyden chamber. Statistical significance was evaluated using the unpaired Student&#8217;s <italic>t</italic> test. The median values are plotted on the graphs; *&#160;<italic>P</italic>&#160;&lt;&#160;0.005, <italic>n</italic>&#160;=&#160;11. Both G<sub>i</sub> inhibitor PTX (100&#160;ng/ml, <bold>b</bold>) and PI3K inhibitor LY294002 (10&#160;&#956;M, <bold>c</bold>) block Shh-induced (1&#160;&#956;g/ml) chemotaxis of peripheral monocytes. The median values are plotted on the graphs; *&#160;<italic>P</italic>&#160;&lt;&#160;0.005, <italic>n</italic>&#160;=&#160;11</p>
###xml 601 1155 601 1151 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32"><bold>a</bold> Cyclopamine (<italic>CP</italic>) inhibits Shh-induced monocyte chemotaxis. Monocytes were pretreated with CP (10&#160;&#956;M) for 15&#160;min and chemotactic response to Shh (1&#160;&#956;g/ml) was measured using the modified Boyden chamber. Statistical significance was evaluated using the unpaired Student&#8217;s <italic>t</italic> test. The median values are plotted on the graphs; *&#160;<italic>P</italic>&#160;&lt;&#160;0.005, <italic>n</italic>&#160;=&#160;11. Both G<sub>i</sub> inhibitor PTX (100&#160;ng/ml, <bold>b</bold>) and PI3K inhibitor LY294002 (10&#160;&#956;M, <bold>c</bold>) block Shh-induced (1&#160;&#956;g/ml) chemotaxis of peripheral monocytes. The median values are plotted on the graphs; *&#160;<italic>P</italic>&#160;&lt;&#160;0.005, <italic>n</italic>&#160;=&#160;11</p></caption>
###xml 1155 1155 1151 1151 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="395_2009_47_Fig3_HTML" id="MO3"/>
###xml 595 1155 595 1151 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="32"><bold>a</bold> Cyclopamine (<italic>CP</italic>) inhibits Shh-induced monocyte chemotaxis. Monocytes were pretreated with CP (10&#160;&#956;M) for 15&#160;min and chemotactic response to Shh (1&#160;&#956;g/ml) was measured using the modified Boyden chamber. Statistical significance was evaluated using the unpaired Student&#8217;s <italic>t</italic> test. The median values are plotted on the graphs; *&#160;<italic>P</italic>&#160;&lt;&#160;0.005, <italic>n</italic>&#160;=&#160;11. Both G<sub>i</sub> inhibitor PTX (100&#160;ng/ml, <bold>b</bold>) and PI3K inhibitor LY294002 (10&#160;&#956;M, <bold>c</bold>) block Shh-induced (1&#160;&#956;g/ml) chemotaxis of peripheral monocytes. The median values are plotted on the graphs; *&#160;<italic>P</italic>&#160;&lt;&#160;0.005, <italic>n</italic>&#160;=&#160;11</p></caption><graphic position="anchor" xlink:href="395_2009_47_Fig3_HTML" id="MO3"/></fig>
To check the specificity of Shh-induced chemotaxis, we pretreated isolated monocytes with CP, a selective inhibitor of Hh signaling. The steroidal alkaloid CP specifically inhibits the Hh pathway by direct binding to Smo and induces a conformational shift leading to Smo inactivation [8]. This pretreatment of monocytes had no effect on chemokinesis. However, CP completely inhibited Shh-induced chemotaxis (Fig. 3a). CP did not abrogate monocyte chemotaxis induced by MCP-1 (data not shown). These results indicate that the chemotactic activity of Shh is specific and dependent on Smo activity.Fig. 3a Cyclopamine (CP) inhibits Shh-induced monocyte chemotaxis. Monocytes were pretreated with CP (10 muM) for 15 min and chemotactic response to Shh (1 mug/ml) was measured using the modified Boyden chamber. Statistical significance was evaluated using the unpaired Student's t test. The median values are plotted on the graphs; * P < 0.005, n = 11. Both Gi inhibitor PTX (100 ng/ml, b) and PI3K inhibitor LY294002 (10 muM, c) block Shh-induced (1 mug/ml) chemotaxis of peripheral monocytes. The median values are plotted on the graphs; * P < 0.005, n = 11
###end p 31
###begin p 32
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 15 17 15 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CP</italic>
###xml 274 275 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 329 330 327 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 340 341 338 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 354 355 352 353 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 382 383 380 381 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 422 423 419 420 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 537 538 533 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 548 549 544 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
a Cyclopamine (CP) inhibits Shh-induced monocyte chemotaxis. Monocytes were pretreated with CP (10 muM) for 15 min and chemotactic response to Shh (1 mug/ml) was measured using the modified Boyden chamber. Statistical significance was evaluated using the unpaired Student's t test. The median values are plotted on the graphs; * P < 0.005, n = 11. Both Gi inhibitor PTX (100 ng/ml, b) and PI3K inhibitor LY294002 (10 muM, c) block Shh-induced (1 mug/ml) chemotaxis of peripheral monocytes. The median values are plotted on the graphs; * P < 0.005, n = 11
###end p 32
###begin title 33
Requirement of G-proteins and PI3 K for Shh-induced chemotaxis of monocytes
###end title 33
###begin p 34
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 418 419 411 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 526 527 515 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 542 543 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
Intracellular chemokine receptor signaling depends on coupling to heterotrimeric G-proteins, usually of the Gi-type [19]. To assess whether Shh-induced chemotaxis is mediated by Gi proteins, we pretreated monocytes with pertussis toxin (PTX), a specific inhibitor of Galphai/o, for 15 min and stimulated with an optimized concentration of Shh (1 mug/ml). Pretreatment with PTX did not affect chemokinesis (89 +/- 22%, P = 0.974); however, Shh-induced chemotaxis of monocytes (165 +/- 25%) was impaired by PTX to 62.1 +/- 30% (P < 0.001, Fig. 3b). These data suggest that Shh-mediated chemotaxis requires signaling via the activation of Galphai.
###end p 34
###begin p 35
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 471 472 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 525 526 523 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 627 628 621 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
The binding of a chemoattractant to its receptor leads to an increased activation of PI3K and cell polarization [34]. Recent studies reported that Shh also regulates some processes through the PI3K/Akt pathway [17, 31]. To investigate the role of the PI3K pathway in Shh-induced migration, we pretreated monocytes with the specific PI3K inhibitor LY294002 for 15 min prior to the chemotaxis assay. LY294002 inhibited both chemokinesis and chemotaxis induced by Shh (Fig. 3c). Chemokinesis was reduced from 100 to 52 +/- 26% (P = 0.001), while Shh-induced chemotaxis was significantly decreased from 165.7 +/- 16 to 35 +/- 13% (P < 0.005). Overall, our data suggest that Shh-mediated chemotaxis of monocytes involves PI3K and Gi proteins.
###end p 35
###begin title 36
###xml 83 88 <span type="species:ncbi:9606">human</span>
Diabetes mellitus type 2, but not CAD, negatively affects Shh-induced migration of human peripheral monocytes
###end title 36
###begin p 37
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
###xml 96 103 <span type="species:ncbi:9606">patient</span>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
###xml 395 403 <span type="species:ncbi:9606">patients</span>
Abnormalities in monocyte function may be responsible for impaired collateral growth in certain patient subsets [10]. It has been demonstrated that CAD patients with DM have a reduced ability to develop collateral blood vessels [42]. To check whether the Hh signaling pathway is affected by CAD and DM, we compared the migratory response to Shh of monocytes isolated from CTR, CAD-DM and CAD+DM patients.
###end p 37
###begin p 38
###xml 178 179 173 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 282 283 275 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 308 309 301 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 324 325 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 328 334 321 327 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 334 335 327 328 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 520 524 512 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">line</italic>
###xml 554 557 546 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">box</italic>
###xml 586 594 578 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">whiskers</italic>
###xml 613 614 605 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 642 643 634 635 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 655 656 647 648 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 334 989 327 975 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39"><bold>a</bold> Shh-induced (1&#160;&#956;g/ml) chemotaxis of monocytes isolated from CTR, CAD&#8722;DM or CAD+DM patients. The median values are plotted; ns; nonsignificant versus unstimulated control. The median (<italic>line</italic>), 25th and 75th percentiles (<italic>box</italic>), 5th and 95th percentiles (<italic>whiskers</italic>) are presented. *&#160;<italic>P</italic>&#160;&lt;&#160;0.005. The level of Ptc (<bold>b</bold>), and Ihh (<bold>c</bold>) gene expression on monocytes isolated from CTR, CAD&#8722;DM and CAD+DM patients. RNA isolated from monocytes was subjected to RT-PCR. &#946;-actin cDNA product served as internal standard to normalize Ptc and Ihh. Signal intensity of Ptc and Ihh mRNA bands was quantified by densitometry and compared with the internal standard &#946;-actin</p>
###xml 334 989 327 975 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="39"><bold>a</bold> Shh-induced (1&#160;&#956;g/ml) chemotaxis of monocytes isolated from CTR, CAD&#8722;DM or CAD+DM patients. The median values are plotted; ns; nonsignificant versus unstimulated control. The median (<italic>line</italic>), 25th and 75th percentiles (<italic>box</italic>), 5th and 95th percentiles (<italic>whiskers</italic>) are presented. *&#160;<italic>P</italic>&#160;&lt;&#160;0.005. The level of Ptc (<bold>b</bold>), and Ihh (<bold>c</bold>) gene expression on monocytes isolated from CTR, CAD&#8722;DM and CAD+DM patients. RNA isolated from monocytes was subjected to RT-PCR. &#946;-actin cDNA product served as internal standard to normalize Ptc and Ihh. Signal intensity of Ptc and Ihh mRNA bands was quantified by densitometry and compared with the internal standard &#946;-actin</p></caption>
###xml 989 989 975 975 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="395_2009_47_Fig4_HTML" id="MO4"/>
###xml 328 989 321 975 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="39"><bold>a</bold> Shh-induced (1&#160;&#956;g/ml) chemotaxis of monocytes isolated from CTR, CAD&#8722;DM or CAD+DM patients. The median values are plotted; ns; nonsignificant versus unstimulated control. The median (<italic>line</italic>), 25th and 75th percentiles (<italic>box</italic>), 5th and 95th percentiles (<italic>whiskers</italic>) are presented. *&#160;<italic>P</italic>&#160;&lt;&#160;0.005. The level of Ptc (<bold>b</bold>), and Ihh (<bold>c</bold>) gene expression on monocytes isolated from CTR, CAD&#8722;DM and CAD+DM patients. RNA isolated from monocytes was subjected to RT-PCR. &#946;-actin cDNA product served as internal standard to normalize Ptc and Ihh. Signal intensity of Ptc and Ihh mRNA bands was quantified by densitometry and compared with the internal standard &#946;-actin</p></caption><graphic position="anchor" xlink:href="395_2009_47_Fig4_HTML" id="MO4"/></fig>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 202 210 <span type="species:ncbi:9606">patients</span>
###xml 419 427 <span type="species:ncbi:9606">patients</span>
###xml 724 732 <span type="species:ncbi:9606">patients</span>
Shh (1 mug/ml) did stimulate migration of monocytes from CAD-DM patients. However, the stimulation of migration was lower in CAD-DM compare to CTR (134 +/- 44 vs. 172.5 +/- 90%, P = 0.354). In diabetic patients (CAD+DM) Shh failed to induce monocyte migration (94.3 +/- 27 vs. CTR, P < 0.001 and vs. CAD-DM, P = 0.033; Fig. 4a).Fig. 4a Shh-induced (1 mug/ml) chemotaxis of monocytes isolated from CTR, CAD-DM or CAD+DM patients. The median values are plotted; ns; nonsignificant versus unstimulated control. The median (line), 25th and 75th percentiles (box), 5th and 95th percentiles (whiskers) are presented. * P < 0.005. The level of Ptc (b), and Ihh (c) gene expression on monocytes isolated from CTR, CAD-DM and CAD+DM patients. RNA isolated from monocytes was subjected to RT-PCR. beta-actin cDNA product served as internal standard to normalize Ptc and Ihh. Signal intensity of Ptc and Ihh mRNA bands was quantified by densitometry and compared with the internal standard beta-actin
###end p 38
###begin p 39
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 186 190 185 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">line</italic>
###xml 220 223 219 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">box</italic>
###xml 252 260 251 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">whiskers</italic>
###xml 279 280 278 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 308 309 307 308 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 321 322 320 321 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 85 93 <span type="species:ncbi:9606">patients</span>
###xml 390 398 <span type="species:ncbi:9606">patients</span>
a Shh-induced (1 mug/ml) chemotaxis of monocytes isolated from CTR, CAD-DM or CAD+DM patients. The median values are plotted; ns; nonsignificant versus unstimulated control. The median (line), 25th and 75th percentiles (box), 5th and 95th percentiles (whiskers) are presented. * P < 0.005. The level of Ptc (b), and Ihh (c) gene expression on monocytes isolated from CTR, CAD-DM and CAD+DM patients. RNA isolated from monocytes was subjected to RT-PCR. beta-actin cDNA product served as internal standard to normalize Ptc and Ihh. Signal intensity of Ptc and Ihh mRNA bands was quantified by densitometry and compared with the internal standard beta-actin
###end p 39
###begin p 40
###xml 340 341 340 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 400 401 400 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 435 436 435 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 539 540 539 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 390 398 <span type="species:ncbi:9606">patients</span>
The chronic inflammation associated with DM could affect the expression of the Hh receptor Ptc on monocytes, which might explain the altered chemotactic response in DM. The RT-PCR-based analysis of Ptc expression on monocytes from CTR, CAD-DM and CAD+DM patients revealed that Ptc expression was upregulated in both CAD-DM and CAD+DM (Fig. 4b). The fold of increase was 5.4-fold for CAD-DM patients (P = 0.045) and 11-fold for CAD+DM (P = 0.004). In contrast, there were no statistically significant differences in expression of Ihh (Fig. 4c), Dhh, Smo, Gli3, Hip and SUFU mRNA (data not shown). Thus, alterations of Hh signaling in CAD-DM and CAD+DM monocytes could only be observed at the level of the receptor Ptc.
###end p 40
###begin p 41
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 196 204 <span type="species:ncbi:9606">patients</span>
A high interindividual variability of Ptc expression in monocytes from CAD-DM patients was noticed. Therefore, we checked the correlation of monocyte migration with Ptc expression level for these patients. The results demonstrated the tendency that monocytes showing reduced migration express higher level of Ptc. However, this correlation was not statistically significant.
###end p 41
###begin p 42
###xml 237 245 <span type="species:ncbi:9606">patients</span>
###xml 317 324 <span type="species:ncbi:9606">patient</span>
###xml 399 406 <span type="species:ncbi:9606">patient</span>
Upregulation of the receptor Ptc is a direct indication of Hh signaling activation, since it is a Hh target gene. Gli1 and Hip1 are two other Hh target genes. To confirm the possible activation of Hh signaling in monocytes from diabetic patients, we analyzed Gli1 and Hip1 mRNA expression on monocytes from different patient groups. Neither Gli1 nor Hip1 mRNA expression in monocytes from different patient groups was detected (data not shown). Thus, our novel data indicate significant alterations of the Hh signaling primarily at the level of receptor Ptc.
###end p 42
###begin title 43
###xml 49 54 <span type="species:ncbi:9606">human</span>
The receptor Ptc colocalizes with macrophages in human atherosclerotic plaques
###end title 43
###begin p 44
###xml 372 373 372 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 450 456 450 456 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;5</label>
###xml 799 816 799 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">magnified inserts</italic>
###xml 456 824 456 824 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="45">Expression of Ptc in an advanced, stable human aortic atherosclerotic lesion. Immunohistological analysis demonstrates that approximately 80% of macrophages were positive for both Ptc and CD68 (merge). Brown color indicates positivity. Sections were counterstained with hematoxylin. Magnification for upper panels is &#215;10 and for lower panels (<italic>magnified inserts</italic>) is &#215;40</p>
###xml 456 824 456 824 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="45">Expression of Ptc in an advanced, stable human aortic atherosclerotic lesion. Immunohistological analysis demonstrates that approximately 80% of macrophages were positive for both Ptc and CD68 (merge). Brown color indicates positivity. Sections were counterstained with hematoxylin. Magnification for upper panels is &#215;10 and for lower panels (<italic>magnified inserts</italic>) is &#215;40</p></caption>
###xml 824 824 824 824 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="395_2009_47_Fig5_HTML" id="MO5"/>
###xml 450 824 450 824 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>Fig.&#160;5</label><caption><p textid="45">Expression of Ptc in an advanced, stable human aortic atherosclerotic lesion. Immunohistological analysis demonstrates that approximately 80% of macrophages were positive for both Ptc and CD68 (merge). Brown color indicates positivity. Sections were counterstained with hematoxylin. Magnification for upper panels is &#215;10 and for lower panels (<italic>magnified inserts</italic>) is &#215;40</p></caption><graphic position="anchor" xlink:href="395_2009_47_Fig5_HTML" id="MO5"/></fig>
###xml 497 502 <span type="species:ncbi:9606">human</span>
Diabetes mellitus is often associated with accelerated atherosclerosis, which is critically mediated by monocytes/macrophages. We performed staining with specific Ptc antibodies and CD68 antibodies to check whether macrophages in atherosclerotic lesion express Ptc. Our data clearly demonstrate the colocalization of receptor Ptc with CD68, a marker for macrophages (Fig. 5, merge). Non-immune IgG did not show any positive staining (data not shown).Fig. 5Expression of Ptc in an advanced, stable human aortic atherosclerotic lesion. Immunohistological analysis demonstrates that approximately 80% of macrophages were positive for both Ptc and CD68 (merge). Brown color indicates positivity. Sections were counterstained with hematoxylin. Magnification for upper panels is x10 and for lower panels (magnified inserts) is x40
###end p 44
###begin p 45
###xml 343 360 343 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">magnified inserts</italic>
###xml 41 46 <span type="species:ncbi:9606">human</span>
Expression of Ptc in an advanced, stable human aortic atherosclerotic lesion. Immunohistological analysis demonstrates that approximately 80% of macrophages were positive for both Ptc and CD68 (merge). Brown color indicates positivity. Sections were counterstained with hematoxylin. Magnification for upper panels is x10 and for lower panels (magnified inserts) is x40
###end p 45
###begin title 46
Discussion
###end title 46
###begin p 47
In this study, we present data supporting a role for Shh/Ihh in stimulation of monocyte chemotaxis. We have not used Dhh for our experiments, because up to now there is no evidence that Dhh is expressed in vascular endothelial cell or vascular smooth muscle cells. Our data demonstrate that both Shh and Ihh stimulate monocyte chemotaxis at the optimal concentration for Shh 1 mug/ml and for Ihh 2.5 mug/ml. Chemotaxis induced by Shh was specific and Smo-dependent. Moreover, Shh activates classical intracellular signal transduction pathways related to cellular migration such as G-protein-coupled specific receptor pathways or PI3K.
###end p 47
###begin p 48
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 642 649 642 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 783 785 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
###xml 642 649 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
The Shh concentration, which stimulates a maximum effect, is rather high in comparison with other known chemoattractants such as MCP-1, MIPs and fractalkine [25]. This may be explained as follows: Hh proteins undergo two posttranslational processing events that result in the covalent addition of cholesterol at the C-terminus [30] and a long-chain fatty acid on the N-terminal cysteine [34]. In addition to tethering the protein to the surface of the cell in which it is synthesized, lipid modification greatly stimulates biological activity of the protein [28, 37]. Recombinant Shh used in these experiments was expressed and purified from E. coli, where it does not undergo those hydrophobic modifications. Recombinant Shh is therefore less potent that natural modified proteins [38].
###end p 48
###begin p 49
###xml 194 195 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 616 618 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">41</xref>
Our current study was not designed to identify the physiological source of Shh that could influence monocyte migration. Nevertheless, it has already been demonstrated that vascular endothelial [4] and smooth muscle cells [25] express Shh. It is thus conceivable that Shh expressed in these cells may attract monocytes into a vessel. Moreover, altered expression of Shh has been reported in a variety of different pathological conditions such as tumorgenesis [14] and ischemic injury [21]. Expression of both Shh and Ptc was increased in cardiac ischemia. Shh expression was upregulated at the sites of inflammation [29] and repair [41].
###end p 49
###begin p 50
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 331 332 331 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 1189 1190 1188 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 1454 1456 1453 1455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 172 179 <span type="species:ncbi:9606">patient</span>
###xml 217 225 <span type="species:ncbi:9606">patients</span>
###xml 395 403 <span type="species:ncbi:9606">patients</span>
###xml 675 683 <span type="species:ncbi:9606">patients</span>
###xml 794 802 <span type="species:ncbi:9606">patients</span>
###xml 1164 1172 <span type="species:ncbi:9606">patients</span>
Recent reports have indicated that abnormalities in monocyte function may be one of the factors responsible for reduced vessel growth and vascular complications in certain patient groups [39]. Monocytes from diabetic patients show a migration defect [40], reduced phagocytosis [20, 26] and increased adhesion to endothelial cells [9]. The present study demonstrates that monocytes from diabetic patients do not respond to Shh at the most efficient concentration in CTR, i.e. 1 mug/ml. This impaired chemotactic response was associated with a 11-fold increase of Ptc mRNA expression in diabetic monocytes. The increase of Ptc expression could be also observed for some CAD-DM patients; however, the difference in expression was not statistically significant in comparison to control subjects (3 patients from 10 had higher level of Ptc expression compared to control). However, there was no significant difference in mRNA expression between different groups for ligands Ihh and Dhh and downstream Hh signaling components Smo and SUFU. Previously, impaired chemotactic response of monocytes associated with increased surface expression of receptors was observed for patients with DM type 1 [5]. Similar effect was observed for blood monocytes from epithelial ovarian cancer. Notwithstanding the increased levels of CCR2 and CCR5 detected on ascitic monocytes, in comparison to that of normal donors, migration response to their ligand RANTES was impaired [16].
###end p 50
###begin p 51
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 187 191 <span type="species:ncbi:10090">mice</span>
Diabetes mellitus type 2 is often associated with obesity. It has been reported that the Hh signaling pathway was less active in obese compared to lean mice. Two models have been tested, mice invalidated in leptine (ob/ob) and high-fat diet induced obesity. So far all experiments leading to a stimulation of Hh signaling in vivo result in an enlarged body mass and conversely, an inhibition of the pathway prevents weight gain [11]. We did not observe significant differences between CAD-DM and CAD+DM with regards to BMI. Therefore, it is unlikely that an excess of adipose mass, which characterizes obesity and is often associated with diabetes, may play a role in disregulation of Hh pathway.
###end p 51
###begin p 52
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">41</xref>
###xml 400 410 400 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 345 353 <span type="species:ncbi:9606">patients</span>
###xml 400 410 <span type="species:ncbi:7227">Drosophila</span>
###xml 573 578 <span type="species:ncbi:9606">human</span>
###xml 668 676 <span type="species:ncbi:9606">patients</span>
Moreover, diabetes mellitus is also accompanied by a systemic low-grade inflammation and it is an important factor in accelerating atherosclerosis. It has been reported that LPS-induced Ptc expression in macrophages after 18 h in culture [41]. Thus, low-grade inflammation could upregulate expression of Ptc on circulating monocytes of diabetes patients. In addition, it has been previously shown in Drosophila that to achieve maximal pathway activity, large excess (more than 50-fold) of Smo over Ptc is required [36]. If similar regulation of Hh signaling applies to the human system, the strong upregulation of Ptc and preserved expression level of Smo in diabetic patients could explain the observed defect in Hh signaling.
###end p 52
###begin p 53
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 475 476 475 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 618 621 618 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 799 800 799 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 628 633 <span type="species:ncbi:10090">mouse</span>
###xml 900 905 <span type="species:ncbi:9606">human</span>
###xml 1209 1214 <span type="species:ncbi:9606">human</span>
Monocytes/macrophages are recognized as one of the principal cell types in the pathology of atherosclerosis [43, 44]. Accumulating evidence suggests that the Hh pathway is involved in peripheral immunity and tissue remodeling [21, 23]. Expression of Shh and Ptc is upregulated in small bowel allografts undergoing chronic rejection. Systemic treatment with a neutralizing anti-Shh antibody reduced tissue remodeling, fibrosis and vascular occlusion of the intestinal grafts [7]. The cells that expressed Ptc in the intestinal grafts undergoing chronic rejection were mainly macrophages. In a recent study using an ApoE-/--based mouse model of atherosclerosis, inhibition of Shh using specific antibodies resulted in a pro-atherosclerotic phenotype secondary to enhanced lipid uptake in macrophages [3]. Our novel data do support the idea that inhibition of Shh may be pro-atherogenic. Macrophages in human atherosclerotic plaques express high levels of receptor Ptc. The diabetes-related inhibition of macrophages may prevent their clearance from atherosclerotic plaques. This could be a novel molecular mechanism promoting atherosclerosis; however, its functional relevance and extent in the pathogenesis of human atherosclerosis remains to be determined.
###end p 53
###begin p 54
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
Thus, our data represent the first example of an endogenous metabolic abnormality, namely DM, which is associated with a functional inhibition of the Hh signaling pathway. Likewise, this impaired monocyte function is likely to be associated with impaired arteriogenesis and impaired wound healing [35, 39]. Identification of novel signal transduction pathways regulating monocyte chemotaxis can indicate unique targets for preventive therapies for treatment of chronic inflammatory diseases.
###end p 54
###begin p 55
###xml 57 64 <span type="species:ncbi:9606">patient</span>
We wish to acknowledge the support from Moniek Baggen in patient recruitment. This study was supported in part by grant VEGF therapies (QLRT-2001-01955) from the European Commission, and by the Cardiovascular Research Institute Maastricht (CARIM).
###end p 55
###begin p 56
###xml 0 30 0 30 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Conflict of interest statement</bold>
Conflict of interest statement None
###end p 56
###begin p 57
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 57
###begin title 58
References
###end title 58
###begin article-title 59
Topical sonic hedgehog gene therapy accelerates wound healing in diabetes by enhancing endothelial progenitor cell-mediated microvascular remodeling
###end article-title 59
###begin article-title 60
###xml 13 18 <span type="species:ncbi:9606">human</span>
Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
###end article-title 60
###begin article-title 61
###xml 45 49 <span type="species:ncbi:10090">mice</span>
Disruption of hedgehog signalling in ApoE-/- mice reduces plasma lipid levels, but increases atherosclerosis due to enhanced lipid uptake by macrophages
###end article-title 61
###begin article-title 62
###xml 54 59 <span type="species:ncbi:9606">human</span>
Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation
###end article-title 62
###begin article-title 63
An increased MRP8/14 expression and adhesion, but a decreased migration towards proinflammatory chemokines of type 1 diabetes monocytes
###end article-title 63
###begin article-title 64
The morphogen sonic hedgehog is an axonal chemoattractant that collaborates with netrin-1 in midline axon guidance
###end article-title 64
###begin article-title 65
###xml 102 105 <span type="species:ncbi:10116">rat</span>
Inhibition of sonic hedgehog signaling reduces chronic rejection and prolongs allograft survival in a rat orthotopic small bowel transplantation model
###end article-title 65
###begin article-title 66
Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened
###end article-title 66
###begin article-title 67
Activation of peripheral blood CD14+ monocytes occurs in diabetes
###end article-title 67
###begin article-title 68
The hedgehog signaling network
###end article-title 68
###begin article-title 69
Hedgehog and adipogenesis: fat and fiction
###end article-title 69
###begin article-title 70
Hedgehog signaling in germ cell migration
###end article-title 70
###begin article-title 71
###xml 121 126 <span type="species:ncbi:10090">mouse</span>
Indian hedgehog activates hematopoiesis and vasculogenesis and can respecify prospective neurectodermal cell fate in the mouse embryo
###end article-title 71
###begin article-title 72
Hedgehog signaling promotes prostate xenograft tumor growth
###end article-title 72
###begin article-title 73
Innate immunity and angiogenesis
###end article-title 73
###begin article-title 74
###xml 45 50 <span type="species:ncbi:9606">human</span>
Migration deficit in monocyte-macrophages in human ovarian cancer
###end article-title 74
###begin article-title 75
Sonic hedgehog protein promotes bone marrow-derived endothelial progenitor cell proliferation, migration and VEGF production via PI 3-kinase/Akt signaling pathways
###end article-title 75
###begin article-title 76
Molecular pathways regulating pro-migratory effects of Hedgehog signaling
###end article-title 76
###begin article-title 77
G protein-coupled receptor roles in cell migration and cell death decisions
###end article-title 77
###begin article-title 78
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Phagocytotic activity on monocytes from diabetic patients
###end article-title 78
###begin article-title 79
Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling
###end article-title 79
###begin article-title 80
Fibroblast growth factor signals regulate a wave of Hedgehog activation that is essential for coronary vascular development
###end article-title 80
###begin article-title 81
Sonic hedgehog promotes cell cycle progression in activated peripheral CD4(+) T lymphocytes
###end article-title 81
###begin article-title 82
Sonic hedgehog promotes the migration and proliferation of optic nerve oligodendrocyte precursors
###end article-title 82
###begin article-title 83
Biomechanical regulation of hedgehog signaling in vascular smooth muscle cells in vitro and in vivo
###end article-title 83
###begin article-title 84
###xml 56 60 <span type="species:ncbi:10090">mice</span>
Phagocytosis of apoptotic cells by macrophages from NOD mice is reduced
###end article-title 84
###begin article-title 85
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 61 76 <span type="species:ncbi:262775">Desert hedgehog</span>
Comparative biological responses to human Sonic, Indian, and Desert hedgehog
###end article-title 85
###begin article-title 86
###xml 51 56 <span type="species:ncbi:9606">human</span>
Identification of a palmitic acid-modified form of human Sonic hedgehog
###end article-title 86
###begin article-title 87
The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors
###end article-title 87
###begin article-title 88
Cholesterol modification of hedgehog signaling proteins in animal development
###end article-title 88
###begin article-title 89
Phosphoinositide 3-kinase and Akt are essential for Sonic hedgehog signaling
###end article-title 89
###begin article-title 90
Factors regulating arteriogenesis
###end article-title 90
###begin article-title 91
###xml 42 45 <span type="species:ncbi:10116">rat</span>
Indian hedgehog promotes the migration of rat activated pancreatic stellate cells by increasing membrane type-1 matrix metalloproteinase on the plasma membrane
###end article-title 91
###begin article-title 92
Roles of PI3Ks in leukocyte chemotaxis and phagocytosis
###end article-title 92
###begin article-title 93
Expression of the developmental Sonic hedgehog (Shh) signalling pathway is up-regulated in chronic lung fibrosis and the Shh receptor patched 1 is present in circulating T lymphocytes
###end article-title 93
###begin article-title 94
Patched acts catalytically to suppress the activity of Smoothened
###end article-title 94
###begin article-title 95
###xml 20 25 <span type="species:ncbi:9606">human</span>
Enhanced potency of human Sonic hedgehog by hydrophobic modification
###end article-title 95
###begin article-title 96
###xml 122 127 <span type="species:ncbi:9606">human</span>
Commercially available recombinant sonic hedgehog up-regulates Ptc and modulates the cytokine and chemokine expression of human macrophages: an effect mediated by endotoxin contamination?
###end article-title 96
###begin article-title 97
Impaired collateral development in diabetes: potential cellular mechanisms and therapeutic implications
###end article-title 97
###begin article-title 98
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: a potential predictor for the individual capacity to develop collaterals
###end article-title 98
###begin article-title 99
Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer
###end article-title 99
###begin article-title 100
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Impaired acute collateral recruitment as a possible mechanism for increased cardiac adverse events in patients with diabetes mellitus
###end article-title 100
###begin article-title 101
Inflammatory mediators in atherosclerotic vascular disease
###end article-title 101
###begin article-title 102
The role of inflammatory cytokines in endothelial dysfunction
###end article-title 102

